@RedChip RedChip

RedChip appears to be hosting investor webinars with various companies, including Bullfrog AI ($BFRG), Calidi Biotherapeutics ($CLDI), Fathom Holdings ($FTHM), and Fibrobiologics ($FBLG). These webinars aim to provide insights into the companies' growth strategies, innovative approaches, and future prospects. RedChip also introduced RedChat, a new platform for small-cap research that provides instant answers and verified data.

Engagements: [------] #

Mentions: [--] #

Followers: [-----] #

CreatorRank: [-------] #

Social Influence

Social category influence stocks finance cryptocurrencies exchanges countries technology brands currencies automotive brands travel destinations social networks

Social topic influence ceo #1122, ai, $nva #4, nasdaq, stocks, future, $aent #1, $aspi #2, company, $bfrg

Top accounts mentioned or mentioned by @novaminerals @aspisotopes @fibrobiologics @greenwichls @calidibio @connectbiopharm @cirmnews @northwesternu @cityofhope @thelancet @lanternpharma @niocorp @fatpipeinc @jcventerinst @lieberinstitute @harvard @xtiaerospace @georgetown @greenpowerbus @troyaikman

Top assets mentioned Nova Minerals Limited (NVA) ASP Isotopes Inc. (ASPI) BullFrog AI Holdings, Inc. (BFRG) Jupiter Neurosciences Inc. (JUNS) Pfizer, Inc. (PFE) Connect Biopharma Holdings Limited (CNTB) Greenwich LifeSciences, Inc. (GLSI) Lantern Pharma Inc. (LTRN) FatPipe, Inc. (FATN) Amgen, Inc. (AMGN) Teck Resources Limited (TECK) Kinross Gold Corporation (KGC) U.S. GoldMining Inc. (USGO) NovaGold Resources Inc. (NG) Hecla Mining Company (HL) Ninja Squad Token (NST) Eli Lilly and Company (LLY) GreenPower Motor Company Inc. (GP) Merck & Co., Inc. (MRK) Gilead Sciences, Inc. (GILD) AbbVie Inc (ABBV) Fathom Holdings Inc (FTHM) Vertex Protocol (VRTX) MP Materials Corp. (MP) NVIDIA Corp. (NVDA) Perpetua Resources Corp. Common Shares (PPTA) Recursion Pharmaceuticals, Inc. (RXRX) Johnson & Johnson (JNJ) Regeneron Pharmaceuticals Inc (REGN) Moderna Inc (MRNA) Schrodinger, Inc. (SDGR) Venu Holding Corporation (VENU) AstraZeneca PLC (AZN)

Top Social Posts

Top posts by engagements in the last [--] hours

"RedChip TV Highlights Royalty Management (NASDAQ: RMCO) & Mobilicom Limited (NASDAQ: MOB) This Week #RedChip #Stocks #Investing #SmallCap http://ow.ly/sUXv1054vX2 http://ow.ly/sUXv1054vX2"
X Link 2023-12-03T01:21Z [----] followers, [---] engagements

"Mobilicom Limited (NASDAQ:MOB): Shaping the Future of Drone Tech #RedChip #Stocks #Investing #SmallCap http://ow.ly/5Z3R1056aKw http://ow.ly/5Z3R1056aKw"
X Link 2023-12-19T17:32Z [----] followers, [---] engagements

"RedChip TV Highlights Mobilicom Limited (NASDAQ : MOB) & Lytus Technologies (NASDAQ: LYT) This Week #RedChip #Stocks #Investing #SmallCap http://ow.ly/trvC105mYKo http://ow.ly/trvC105mYKo"
X Link 2024-03-22T14:42Z [----] followers, [--] engagements

"☀ Solar energy meets blockchain SolarMax Technology $SMXT has signed an MOU with SOS Limited to develop 300MW of solar power for cryptocurrency mining operations in the U.S. 📍 Nevada Texas and Florida will lead the charge in sustainable crypto energy. 🔗 Read the full story: $SMXT #SolarEnergy #RenewableEnergy #GreenEnergy #Sustainability #CleanEnergy #Investing #SolarPower #Stocks #SolarTechnology #FinancialNews #cryptocurrency #CryptoNews https://www.redchip.com/stocks/smxt/news.phpstoryId=6563896954437525 https://www.redchip.com/stocks/smxt/news.phpstoryId=6563896954437525"
X Link 2024-12-10T14:51Z [----] followers, [----] engagements

"📢 Greenwich LifeSciences $GLSI Reports Positive Safety Data from Phase III FLAMINGO-01 Trial With no serious adverse events related to GLSI-100 reinforcing its strong safety profile the DSMB recommends the trial continue as planned. 🔬 Why It Matters for Investors: ✅ Phase III Validation Safety data aligns with Phase IIb results supporting GLSI-100s well-tolerated profile. ✅ Market Potential Aims to reduce HER2+ breast cancer recurrences addressing a critical unmet need. ✅ Upcoming Catalysts Immune response data & potential scientific presentations could further de-risk the investment. 🔗"
X Link 2025-03-17T13:26Z [----] followers, [---] engagements

"🚀 Connect Biopharma $CNTB Sets Up for Breakout [----] in Respiratory Care Following a major leadership refresh and U.S. expansion $CNTB is advancing parallel Phase [--] trials in acute asthma & COPD two major unmet needs in respiratory care. 💡 Why It Matters: ✅ No approved biologics for acute asthma or COPD ✅ New exec team brings deep U.S. biopharma expertise ✅ $93.7M in cash funded into [----] & through key [----] data readouts 📄 Full Update: $CNTB $GSK $REGN $ARWR $MRK #CNTB #Asthma #COPD #Biotech #ClinicalTrials #RespiratoryCare #Investing #finance"
X Link 2025-03-31T14:43Z [----] followers, [---] engagements

"💨 Connect Biopharma $CNTB: New Phase [--] Data Spotlights Rademikibart as a Standout Asthma Biologic Positive results published in AJRCCM show: 📈 +420 mL FEV Gain in high eosinophil patientsamong the best seen with any biologic ⚡ Rapid Onset: Significant improvement by Week [--] sustained through [--] weeks 📉 Exacerbation Drop: Fewer events despite 2x patient count vs. placebo 🛡 Clean Safety Profile: No hypereosinophiliakey edge over dupilumab 🔬 Why It Matters: With FDA clearance to enter Phase [--] and 2M U.S. patients facing exacerbations annually $CNTB could emerge as a major contender in the"
X Link 2025-03-31T21:09Z [----] followers, [---] engagements

"🚨 Connect Biopharma $CNTB: FDA Clears Path for Dual Phase [--] Trials in Asthma & COPD $CNTB received FDA alignment to launch two first-of-their-kind Phase [--] trials of rademikibart in patients immediately post-exacerbationwhere no biologics are currently approved. 💡 Why It Matters High-Need Window: Trials target 28-day post-attack periodwhen 45% of patients face recurrence Fast-Acting Candidate: Prior data showed lung function boost [--] hrs after 600mg dose Near-Term Milestones: Trials begin Q2 [----] data expected 1H [----] Capital Position: Cash runway extends into [----] This could reshape care"
X Link 2025-04-01T14:50Z [----] followers, 48.7K engagements

"📢 Connect Biopharma $CNTB: Investor Webinar This Tuesday Dont Miss It 🗓 April [--] 4:15 PM EST Connect Biopharma is inviting investors to a live webinar to discuss its strategic roadmap and clinical progressespecially around rademikibart a next-generation IL-4R antibody targeting acute asthma and COPD exacerbations. 💡 Why This Matters for Investors: - FDA Alignment Achieved: Parallel Phase [--] trials for asthma and COPD to launch Q2 2025targeting a $20B+ combined global market. - Clear Path Forward: Data expected in H1 [----] with a cash runway extending into [----]. - Unmet Need Opportunity: No"
X Link 2025-04-10T19:26Z [----] followers, [---] engagements

"📢 Connect Biopharma $CNTB Hosts Investor Webinar Tomorrow at 4:15 PM ET $CNTB invites investors to its upcoming webinar to discuss corporate strategy and pipeline prioritiesincluding next steps for rademikibart in acute asthma and COPD care. 💡 Why This Matters to Investors: - With FDA alignment now secured $CNTB is preparing to launch two parallel Phase [--] trials in Q2 [----] targeting a massive unmet needacute exacerbations of asthma and COPD. This area impacts over [---] million patients annually in the U.S. alone and currently has no approved biologics. With promising early efficacy and a"
X Link 2025-04-14T15:17Z [----] followers, [---] engagements

"Sanofi $SNY Asthma Drug Misses Primary Goal Investors are buzzing about Connect BioPharma $CNTB as it traded 50x average volume on this news Under the new leadership of Barry Quart (CEO) and David Szerkeres (President) $CNTB is making waves with their groundbreaking Phase [--] trials in acute asthma and COPD. Results from these trials could be game-changing for patients and investors alike. The annual U.S. market includes [--] million asthma and [---] million COPD patients experiencing severe exacerbations requiring urgent ER treatment. 📰 $CNTB $GSK $REGN $ARWR $MRK #CNTB #Asthma #COPD #Biotech"
X Link 2025-04-15T20:20Z [----] followers, [---] engagements

"🚨 Connect Biopharma $CNTB to Showcase Respiratory Innovation at ATS [----] Connect Biopharma will present four clinical postersat the American Thoracic Society [----] International Conference spotlighting promising data for its lead candidate rademikibart a next-gen IL-4R antibody for asthma and COPD. 🧬 Why This Matters to Investors: - Strong Clinical Data: Phase 2b data shows rapid clinically meaningful lung function improvementFEV gains seen within [--] hours. - Addressing Large Unmet Need: Targeting acute exacerbations in 2.3M U.S. asthma and COPD patients annuallyan underserved high-need"
X Link 2025-04-24T15:47Z [----] followers, [----] engagements

"📢 Connect Biopharma $CNTB: Investor Webinar Set for May [--] Spotlight on Respiratory Innovation @ConnectBiopharm invites investors to a live webinar on Wednesday May [--] at 4:15 PM EST featuring updates on its lead asset rademikibarta next-gen monoclonal antibody targeting IL-4R with blockbuster potential in asthma and COPD. 💡 Why This Matters to Investors: - Multi-Billion Dollar Market Opportunity: Targeting asthma and COPD with peak sales projections topping $5B globally. - Differentiated Clinical Data: Phase [--] results show rapid superior efficacy and a favorable safety profilestrongly"
X Link 2025-04-30T21:06Z [----] followers, 15.3K engagements

"📢 Connect Biopharma $CNTB to Host Investor Webinar Tomorrow: Spotlight on Respiratory Breakthroughs @ConnectBiopharm invites investors to an exclusive webinar highlighting the strategic direction and clinical progress behind its lead asset rademikibarta next-gen IL-4R monoclonal antibody targeting asthma and COPD. 💡 Why This Matters to Investors: - $5B+ Market Opportunity: Targeting large underserved asthma and COPD indications with acute and chronic applications. - Strong Clinical Results: Robust Phase [--] data shows superior efficacy and safety positioning rademikibart as a potential"
X Link 2025-05-06T19:11Z [----] followers, [---] engagements

"🎙 Connect Biopharma $CNTB: CEO Barry Quart Discusses Transformative Respiratory Pipeline In an exclusive new interview @ConnectBiopharm CEO Barry Quart shares insights into how the company is redefining treatment for asthma and COPD with its lead asset rademikibarta next-gen monoclonal antibody showing best-in-class potential. 💡 Why This Matters for Investors: - Massive Market Potential: Targeting diseases representing $5B in annual opportunity. - Strong Clinical Backing: Global Phase [--] data shows rapid sustained efficacy and a strong safety profile. - Strategic Leadership: U.S.-focused"
X Link 2025-05-07T13:00Z [----] followers, [---] engagements

"📅 Todays the Day: Connect Biopharma $CNTB Investor Webinar Join @ConnectBiopharm this afternoon for an in-depth look at its lead candidate rademikibart a next-gen monoclonal antibody targeting IL-4R with high potential in asthma and COPDmulti-billion-dollar markets with major unmet needs. 🔍 What to Expect: - Insights into clinical strategy and market positioning - Details on Phase [--] results and upcoming trials - Vision from a leadership team with [--] FDA approvals under its belt 💼 This is a key opportunity for investors to hear directly from the team driving $CNTBs next phase of growth. 🔗"
X Link 2025-05-07T14:07Z [----] followers, [---] engagements

"🚨 Connect Biopharma $CNTB Launches Phase [--] Study Targeting Acute Asthma Attacks @ConnectBiopharm has initiated its Seabreeze STAT Asthma Phase [--] trial to evaluate rademikibart as an adjunct therapy for acute asthma exacerbations. The move follows FDA alignment on the final protocol and builds on promising prior data showing rapid lung function improvement within [--] hours. 💡 Why This Matters for Investors: 🔬 First-in-Class Potential: Rademikibart could become the first biologic approved specifically for treating acute asthma attacksa critical unmet need impacting over [--] million ER visits"
X Link 2025-05-13T13:55Z [----] followers, [--] engagements

"🚨 Connect Biopharma $CNTB Launches Phase [--] Seabreeze STAT Study for COPD Exacerbations @ConnectBiopharm has initiated its Phase [--] Seabreeze STAT COPD trial to evaluate rademikibart a next-gen IL-4R antibody for acute exacerbations in COPD patients with type [--] inflammation. 💡 Why This Matters for Investors: - Targeting a Major Gap: No approved biologics currently address rapid treatment for COPD flare-upsimpacting 1.3M ER visits annually in the U.S. - Promising Preclinical Signals: Post-hoc data from prior asthma trials showed significant lung function improvement in COPD-like patients with"
X Link 2025-05-14T15:45Z [----] followers, [---] engagements

"📢 Connect Biopharma $CNTB: Advancing Rademikibart for Acute Asthma & COPD Flares @ConnectBiopharm has launched two Phase [--] trials for rademikibart targeting acute exacerbations in asthma and COPD. This represents a major shift toward biologics in emergency respiratory care with topline data expected in 1H [----]. 💡 Why It Matters to Investors: - Published Phase [--] datashow rapid lung function improvement (+420 mL FEV) in eosinophilic asthmaamong the highest reported. - Positive FDA alignmentand major visibility at ATS [----] with [--] posters accepted. - $84M in cashas of Q1 [----] funding operations"
X Link 2025-05-15T14:23Z [----] followers, [---] engagements

"🧬 Connect Biopharma $CNTB: Rademikibart Shows Fast-Acting Results in Asthma and COPD Exacerbations @ConnectBiopharm unveiled compelling data at ATS [----] showing that its IL-4R inhibitor rademikibart significantly improved lung function (FEV) within [--] hours and reduced acute exacerbations in patients with inflammation-driven asthma. 🧪 Why This Matters for Investors: - Clinical Momentum: Supports ongoing Phase [--] trials in asthma and COPD with topline data expected in 1H [----]. - Differentiated Profile: Preclinical data shows stronger IL-4R binding and a safer eosinophil profile compared to"
X Link 2025-05-20T15:03Z [----] followers, [---] engagements

"📣 Connect Biopharma $CNTB Announces June Investor Conference Presentations @ConnectBiopharm advancing next-gen treatments for asthma and COPD will spotlight its clinical progress at two key investor conferences in June: 🗓 Noble Capital Markets Virtual Conference 📍 June [--] [----] 9:00 a.m. ET 🗓 Jefferies Healthcare Conference 📍 June [--] [----] 7:35 a.m. ET 🔗 💡 What Investors Will Be Watching: $CNTB is advancing rademikibart a promising IL-4R antibody showing rapid clinically meaningful improvement in lung function for asthma patientswith potential to transform care for 2.3M patients annually"
X Link 2025-05-28T14:04Z [----] followers, [----] engagements

"🎥 Missed the FatPipe Networks $FATN Investor Webinar Catch the Replay Now @FatPipe_Incan emerging leader in secure software-defined networkingshared powerful insights in its latest investor webinar including: 🔹 Strong Profitability: $5.2M net income on $18.7M revenue (27.7% margin) 🔹 Recurring Revenue Model: 90%+ gross margins and growing channel-driven sales 🔹 Expanding TAM: Positioned at the intersection of SD-WAN SASE & NMStargeting a $49B+ market by [----] 🔹 Scalable Growth: Long-term contracts global footprint and a capital-efficient SaaS model 💡 Why This Matters for Investors:"
X Link 2025-05-30T17:36Z [----] followers, [---] engagements

"📈 Connect Biopharma $CNTB: Strengthening Clinical Case for Rademikibart Ahead of Late-Stage Development @ConnectBiopharm will present new data at @EAACI_HQ [----] showcasing rademikibarts ability to significantly reduce asthma exacerbations and rapidly improve lung functionin patients with eosinophilic Type [--] asthma. 🔍 Why It Matters: - These results support rademikibarts positioning as a potential best-in-class IL-4R antibody targeting a critical gap in asthma and COPD care for over 2.3M U.S. patientswith acute exacerbations annually. Rapid onset of action and durable control make it a"
X Link 2025-06-03T14:12Z [----] followers, [---] engagements

"🚀 Connect Biopharma $CNTB: Rademikibart Delivers Faster Relief Than Dupixent in Type [--] Asthma At EAACI [----] @ConnectBiopharm showcased data confirming rademikibarts potential best-in-class speeddelivering lung function improvements in under [--] hours compared to [--] days for Dupixent. 📈 Clinical Highlights: - Statistically significant FEV1 improvements within [--] hours via home spirometry. - Up to 74% reduction in exacerbation rates in high eosinophil/FeNO subgroups. - Supports ongoing Phase [--] trials in asthma and COPD; topline data expected 1H [----]. 💡 Why This Matters: Fast-acting efficacy"
X Link 2025-06-13T16:20Z [----] followers, [---] engagements

"🎙 Connect Biopharma $CNTB: CEO Barry Quart Discusses Transformative Respiratory Pipeline In an exclusive new interview @ConnectBiopharm CEO Barry Quart shares insights into how the company is redefining treatment for asthma and COPD with its lead asset rademikibart: a next-gen monoclonal antibody showing best-in-class potential. 💡 Why This Matters for Investors: - Massive Market Potential: Targeting diseases representing $5B in annual opportunity. - Strong Clinical Backing: Global Phase [--] data shows rapid sustained efficacy and a strong safety profile. - Strategic Leadership: U.S.-focused"
X Link 2025-06-25T13:00Z [----] followers, [---] engagements

"🚀 Dont Miss: Live Investor Webinar with Connect Biopharma $CNTB Join @ConnectBiopharm's leadership team on July 15th at 4:15PM EST for a deep dive into their late-stage pipeline targeting asthma & COPDmulti-billion-dollar markets with high unmet need. 🔬 Learn how rademikibarts Phase [--] data signals best-in-class potential and why $CNTB is positioned for late-stage success and value creation through [----]. 🎯 Why This Matters: Peak sales potential: $5B+ across asthma & COPD U.S.-based team with [--] FDA approvals under their belt Strong cash runway through pivotal milestones 📍Reserve Your Spot"
X Link 2025-07-01T12:31Z [----] followers, [---] engagements

"🎙 Connect Biopharma $CNTB: CEO Barry Quart Discusses Transformative Respiratory Pipeline In an exclusive new interview @ConnectBiopharm CEO Barry Quart shares insights into how the company is redefining treatment for asthma and COPD with its lead asset rademikibart: a next-gen monoclonal antibody showing best-in-class potential. 💡 Why This Matters for Investors: - Massive Market Potential: Targeting diseases representing $5B in annual opportunity. - Strong Clinical Backing: Global Phase [--] data shows rapid sustained efficacy and a strong safety profile. - Strategic Leadership: U.S.-focused"
X Link 2025-07-02T13:00Z [----] followers, [---] engagements

"🔔 [--] Week Countdown: Connect Biopharma $CNTB Investor Webinar Hear directly from the @ConnectBiopharm team on July [--] at 4:15PM EST about their bold strategy to redefine severe respiratory care. 💡 Key Focus: Rademikibarts superior Phase [--] efficacy vs. current biologics Upcoming late-stage trials in asthma & COPD Commercial runway through [----] 📊 $CNTB is a compelling biotech story targeting blockbuster markets. Dont miss it. 📍Register Here $CNTB $GSK $REGN $ARWR $MRK #BiotechInvesting #CNTB #InvestorEvents #AsthmaTreatment #COPD"
X Link 2025-07-08T14:12Z [----] followers, [---] engagements

"🎙 Connect Biopharma $CNTB: CEO Barry Quart Discusses Transformative Respiratory Pipeline In an exclusive new interview @ConnectBiopharm CEO Barry Quart shares insights into how the company is redefining treatment for asthma and COPD with its lead asset rademikibart: a next-gen monoclonal antibody showing best-in-class potential. 💡 Why This Matters for Investors: - Massive Market Potential: Targeting diseases representing $5B in annual opportunity. - Strong Clinical Backing: Global Phase [--] data shows rapid sustained efficacy and a strong safety profile. - Strategic Leadership: U.S.-focused"
X Link 2025-07-09T13:00Z [----] followers, [---] engagements

"Connect Biopharma $CNTB: Major Regulatory Milestone in China for Rademikibart Simcere Pharmaceutical $CNTB's exclusive licensee in Greater China has submitted a New Drug Application for rademikibart to treat atopic dermatitis in adults and adolescents. 💡 Why This Matters for Investors: - Large Market Potential: 70M people in China suffer from atopic dermatitis: a major unmet need. - Revenue Opportunity: $CNTB is eligible for up to $110M in milestone payments plus tiered royalties on future net sales. - Pipeline Validation: The submission advances rademikibart CNTBs lead IL-4R antibody across"
X Link 2025-07-09T13:29Z [----] followers, [---] engagements

"🎙 Connect Biopharma $CNTB: CEO Barry Quart Discusses Transformative Respiratory Pipeline In an exclusive new interview @ConnectBiopharm CEO Barry Quart shares insights into how the company is redefining treatment for asthma and COPD with its lead asset rademikibart: a next-gen monoclonal antibody showing best-in-class potential. 💡 Why This Matters for Investors: - Massive Market Potential: Targeting diseases representing $5B in annual opportunity. - Strong Clinical Backing: Global Phase [--] data shows rapid sustained efficacy and a strong safety profile. - Strategic Leadership: U.S.-focused"
X Link 2025-07-16T13:00Z [----] followers, [---] engagements

"💡 Connect Biopharma $CNTB to Present at BTIG Virtual Biotech Conference @ConnectBiopharm will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on July [--] at 9:20 a.m. ET providing insights into its clinical progress and strategic roadmap. Why This Matters to Investors: - Spotlight on Rademikibart: $CNTB's lead asset a next-gen IL-4R-targeting antibody is advancing through global trials for asthma and COPD. - Market Potential: Addressing multi-billion-dollar markets with high unmet need in respiratory care. - Strategic Visibility: Participation underscores $CNTB's"
X Link 2025-07-18T14:28Z [----] followers, [---] engagements

"⚕ Connect Biopharma $CNTB: Strategic Leadership Boost to Accelerate Rademikibarts Path to Market @ConnectBiopharm has appointed biotech veteran Jim Schoeneck to its Board of Directors expanding the board to seven members. Schoeneck brings 40+ years of experience in drug development and commercialization having led multiple public and private biotech companies through major growth and transformation. Why This Matters for Investors: - Leadership Strength: Schoenecks expertise aligns with $CNTB's push to advance rademikibart a potential first-in-class antibody for asthma and COPD. - Clinical"
X Link 2025-07-22T15:40Z [----] followers, [---] engagements

"🎙 Connect Biopharma $CNTB: CEO Barry Quart Discusses Transformative Respiratory Pipeline In an exclusive new interview @ConnectBiopharm CEO Barry Quart shares insights into how the company is redefining treatment for asthma and COPD with its lead asset rademikibart: a next-gen monoclonal antibody showing best-in-class potential. 💡 Why This Matters for Investors: - Massive Market Potential: Targeting diseases representing $5B in annual opportunity. - Strong Clinical Backing: Global Phase [--] data shows rapid sustained efficacy and a strong safety profile. - Strategic Leadership: U.S.-focused"
X Link 2025-07-23T13:00Z [----] followers, [---] engagements

"🔬 Connect Biopharma: Transforming Respiratory Care - Investor Webinar @ConnectBiopharm $CNTB is leading innovation in severe asthma and COPD treatment with rademikibart a next-gen IL-4R monoclonal antibody showing superior efficacy and rapid onset in Phase [--] trials. Why Investors Should Attend: $5B+ market potential across asthma and COPD Strong U.S.-based leadership with [--] prior FDA drug approvals Clear path to late-stage trials and commercialization Reserve your spot for our upcoming investor webinar: $CNTB $GSK $REGN $ARWR $MRK https://bit.ly/3IA3lVF https://bit.ly/3IA3lVF"
X Link 2025-07-23T19:58Z [----] followers, [---] engagements

"📈 @ConnectBiopharm $CNTB: Northland Capital Initiates Coverage with Outperform Rating $7.50 Price Target Northland Capital Markets initiated coverage on Connect Biopharma with an Outperform rating and a $7.50 price target highlighting rademikibarts potential to be the first biologic approved for acute exacerbations in asthma and COPD. Why This Matters for Investors: - Multi-Billion-Dollar Market: Rademikibart targets a $12B+ addressable market across asthma and COPD with no current approved biologic for acute flare-ups. - Strong Growth Catalysts: Two Phase [--] trial readouts expected in 1H"
X Link 2025-07-25T17:14Z [----] followers, [---] engagements

"💡 One Week Away: Connect Biopharma $CNTB Investor Webinar Dont miss the opportunity to hear directly from @ConnectBiopharms leadership on how the company is redefining respiratory treatment with its lead asset rademikibart. What Youll Learn: $3B+ peak sales potential in asthma $2B+ in COPD Differentiated IL-4R antibody backed by strong Phase [--] data Strategic plans for pivotal trials and commercialization Secure your spot for this high-impact investor session: $CNTB $GSK $REGN $ARWR $MRK https://bit.ly/3IHlhxt https://bit.ly/3IHlhxt"
X Link 2025-07-29T15:27Z [----] followers, [---] engagements

"🎙 Connect Biopharma $CNTB: CEO Barry Quart Discusses Transformative Respiratory Pipeline In an exclusive new interview @ConnectBiopharm CEO Barry Quart shares insights into how the company is redefining treatment for asthma and COPD with its lead asset rademikibart: a next-gen monoclonal antibody showing best-in-class potential. Why This Matters for Investors: - Massive Market Potential: Targeting diseases representing $5B in annual opportunity. - Strong Clinical Backing: Global Phase [--] data shows rapid sustained efficacy and a strong safety profile. - Strategic Leadership: U.S.-focused team"
X Link 2025-07-30T13:00Z [----] followers, [---] engagements

"24 Hours Left: Dont Miss Connect Biopharmas Investor Webinar @ConnectBiopharm $CNTB is advancing a best-in-class asset in asthma and COPD with massive market potential. With key milestones ahead now is the time to learn more. Register to attend tomorrow's live session: $CNTB $GSK $REGN $ARWR $MRK https://bit.ly/4kR7NfS https://twitter.com/i/web/status/1952369458351100108 https://bit.ly/4kR7NfS https://twitter.com/i/web/status/1952369458351100108"
X Link 2025-08-04T14:02Z [----] followers, [---] engagements

"Join Connect Biopharma $CNTB's CEO on our investor webinar: live now $CNTB $GSK $REGN $ARWR $MRK RedChip Investor Webinar with Connect Biopharma (Nasdaq: CNTB) https://t.co/kcrxUJPLkh RedChip Investor Webinar with Connect Biopharma (Nasdaq: CNTB) https://t.co/kcrxUJPLkh"
X Link 2025-08-05T20:34Z [----] followers, [---] engagements

"🎙 Connect Biopharma $CNTB: CEO Barry Quart Discusses Transformative Respiratory Pipeline In an exclusive new interview @ConnectBiopharm CEO Barry Quart shares insights into how the company is redefining treatment for asthma and COPD with its lead asset rademikibart: a next-gen monoclonal antibody showing best-in-class potential. Why This Matters for Investors: - Massive Market Potential: Targeting diseases representing $5B in annual opportunity. - Strong Clinical Backing: Global Phase [--] data shows rapid sustained efficacy and a strong safety profile. - Strategic Leadership: U.S.-focused team"
X Link 2025-08-06T13:00Z [----] followers, [---] engagements

"🎥 FatPipe $FATN CEO Interview: Inside a Profitable High-Margin Software Business Dont miss this exclusive conversation with Ragula Bhaskar PhD President & CEO of @FatPipe_Inc $FATN a leader in secure software-defined networking. Why Investors Should Watch: Positioned at the intersection of SD-WAN SASE and NMS: a $49B+ TAM by [----] 90%+ gross margins and a recurring revenue model Global footprint with over [----] enterprise customers Backed by patented tech and a pure-play focus on mission-critical infrastructure FatPipe is delivering results and scaling smart. Watch Now and hear how $FATN plans"
X Link 2025-08-06T13:25Z [----] followers, [---] engagements

"🎥 Greenwich LifeSciences $GLSI: CEO Snehal Patel Discusses GP2 Immunotherapy and Phase III Strategy In our most recent interview CEO Snehal Patel outlines the companys clinical and strategic roadmap for GP2 an immunotherapy designed to prevent breast cancer recurrences in HER2-positive patients following surgery. Key Takeaways for Investors: Robust Phase IIb Data: GP2 achieved over 80% reduction in recurrence rates over five years significantly outperforming existing therapies in the adjuvant setting. Strong Safety Profile: No serious adverse events reported across [---] patients in four"
X Link 2025-08-07T13:40Z [----] followers, [---] engagements

"📍Today at 4:15 PM EST: FatPipe $FATN Investor Webinar Hear how @FatPipe_Inc is scaling in a $49B+ market with strong margins and recurring revenue. 🔗 $FATN $CSCO $ORCL $HPE $FTNT #NASDAQ #TechStocks #Networking #SDWAN #SASE #CloudInfrastructure #finance https://twitter.com/i/web/status/1953491605287055503 https://www.redchip.com/webinar/FATN/89527003978utm_source=X&utm_medium=post&utm_campaign=FATN_webinar https://twitter.com/i/web/status/1953491605287055503 https://www.redchip.com/webinar/FATN/89527003978utm_source=X&utm_medium=post&utm_campaign=FATN_webinar"
X Link 2025-08-07T16:21Z [----] followers, [---] engagements

"🎙 Connect Biopharma $CNTB: CEO Barry Quart Discusses Transformative Respiratory Pipeline In an exclusive new interview @ConnectBiopharm CEO Barry Quart shares insights into how the company is redefining treatment for asthma and COPD with its lead asset rademikibart: a next-gen monoclonal antibody showing best-in-class potential. Why This Matters for Investors: - Massive Market Potential: Targeting diseases representing $5B in annual opportunity. - Strong Clinical Backing: Global Phase [--] data shows rapid sustained efficacy and a strong safety profile. - Strategic Leadership: U.S.-focused team"
X Link 2025-08-13T13:00Z [----] followers, [---] engagements

"💡 Connect Biopharma $CNTB Reports Significant Progress Across Clinical and Corporate Goals in Q2 Key Q2 Achievements: Clinical Momentum: Phase [--] Seabreeze STAT trials in asthma and COPD are actively enrolling with topline data expected 1H [----]. Positive Data Readouts: Results presented at ATS [----] and EAACI [----] highlight rademikibarts differentiated efficacy and safety in eosinophilic-driven type [--] asthma and COPD. Regulatory Milestone: Partner Simcere submitted a new drug application in China for atopic dermatitis unlocking potential milestone payments up to $110M plus royalties. Strategic"
X Link 2025-08-13T13:41Z [----] followers, [---] engagements

"📢 Connect Biopharma $CNTB Partners with NFL Legend Ickey Woods to Expand Asthma Education Nationwide Why This Matters to Investors: Strategic Outreach: Collaboration with the Jovante Woods Foundation will bring asthma awareness and education to new U.S. markets during the [----] NFL season. Addressing Unmet Needs: Focus on acute asthma exacerbations a high-risk area with over 1M ER visits annually and limited targeted treatments. Clinical Pipeline Progress: $CNTB's Phase [--] Seabreeze STAT studies for acute asthma are on track with topline data expected 1H [----] potentially unlocking a"
X Link 2025-08-14T13:49Z [----] followers, [---] engagements

"🔬 Greenwich LifeSciences $GLSI: Boosting Trial Efficiency with In-House Clinical Team @GreenwichLS is shifting strategy by building an internal clinical operations team to manage its Phase III FLAMINGO-01 trial aiming to reduce reliance on costly CROs. Why This Matters to Investors: Cost Savings: Transition to in-house staff is expected to lower trial expenses and reduce baseline burn rate. Increased Efficiency: Dedicated team enhances trial oversight data quality and site monitoring across global locations. Strategic Flexibility: New capabilities pave the way for additional GLSI-100 trials"
X Link 2025-08-19T13:02Z [----] followers, [---] engagements

"🎙 Connect Biopharma $CNTB: CEO Barry Quart Discusses Transformative Respiratory Pipeline In an exclusive new interview @ConnectBiopharm CEO Barry Quart shares insights into how the company is redefining treatment for asthma and COPD with its lead asset rademikibart: a next-gen monoclonal antibody showing best-in-class potential. Why This Matters for Investors: - Massive Market Potential: Targeting diseases representing $5B in annual opportunity. - Strong Clinical Backing: Global Phase [--] data shows rapid sustained efficacy and a strong safety profile. - Strategic Leadership: U.S.-focused team"
X Link 2025-08-20T13:00Z [----] followers, [---] engagements

"🎙 Connect Biopharma $CNTB: CEO Barry Quart Discusses Transformative Respiratory Pipeline In an exclusive new interview @ConnectBiopharm CEO Barry Quart shares insights into how the company is redefining treatment for asthma and COPD with its lead asset rademikibart: a next-gen monoclonal antibody showing best-in-class potential. Why This Matters for Investors: Massive Market Potential: Targeting diseases representing $5B in annual opportunity. Strong Clinical Backing: Global Phase [--] data shows rapid sustained efficacy and a strong safety profile. Strategic Leadership: U.S.-focused team with"
X Link 2025-08-27T13:00Z [----] followers, [---] engagements

"🎥 FatPipe $FATN CEO Interview: Inside a Profitable High-Margin Software Business Dont miss this exclusive conversation with Ragula Bhaskar PhD President & CEO of @FatPipe_Inc $FATN a leader in secure software-defined networking. Why Investors Should Watch: Positioned at the intersection of SD-WAN SASE and NMS: a $49B+ TAM by [----] 90%+ gross margins and a recurring revenue model Global footprint with over [----] enterprise customers Backed by patented tech and a pure-play focus on mission-critical infrastructure FatPipe is delivering results and scaling smart. Watch now: $FATN $AVGO $CSCO $ORCL"
X Link 2025-08-27T13:25Z [----] followers, [---] engagements

"⚛ @ConnectBiopharm $CNTB Engages Investors at Key September Conferences Connect Biopharma will present at two major investor events highlighting its clinical progress and strategic vision in inflammatory diseases: Cantor Global Healthcare Conference Sept. [--] at 3:20 p.m. ET H.C. Wainwright 27th Annual Global Investment Conference Sept. [--] at 9:30 a.m. ET Full Details & Webcast Access: $CNTB $GSK $REGN $ARWR $MRK $VRTX $SNY $AMGN https://bit.ly/4lR0eGP https://bit.ly/4lR0eGP"
X Link 2025-08-27T13:40Z [----] followers, [---] engagements

"Todays the day Join @ASPIsotopes $ASPI CEO Paul Mann live at 4:15 PM EST for an investor Q&A. 👉 Register here: $ASPI $SMR $NNE $OKLO $UUUU $CEG $VST $CCJ $UEC $LEU $GEV $BEP https://bit.ly/45x7Qco https://bit.ly/45x7Qco"
X Link 2025-08-28T13:50Z [----] followers, [----] engagements

"🎙 Connect Biopharma $CNTB: CEO Barry Quart Discusses Transformative Respiratory Pipeline In an exclusive new interview @ConnectBiopharm CEO Barry Quart shares insights into how the company is redefining treatment for asthma and COPD with its lead asset rademikibart: a next-gen monoclonal antibody showing best-in-class potential. Why This Matters for Investors: Massive Market Potential: Targeting diseases representing $5B in annual opportunity. Strong Clinical Backing: Global Phase [--] data shows rapid sustained efficacy and a strong safety profile. Strategic Leadership: U.S.-focused team with"
X Link 2025-09-03T13:00Z [----] followers, [---] engagements

"🎥 FatPipe $FATN CEO Interview: Inside a Profitable High-Margin Software Business Dont miss this exclusive conversation with Ragula Bhaskar PhD President & CEO of @FatPipe_Inc $FATN a leader in secure software-defined networking. Why Investors Should Watch: Positioned at the intersection of SD-WAN SASE and NMS: a $49B+ TAM by [----] 90%+ gross margins and a recurring revenue model Global footprint with over [----] enterprise customers Backed by patented tech and a pure-play focus on mission-critical infrastructure FatPipe is delivering results and scaling smart. Watch now: $FATN $AVGO $CSCO $ORCL"
X Link 2025-09-03T13:25Z [----] followers, 41.7K engagements

"📣 Connect Biopharma $CNTB Spotlights Rademikibart Asthma Data at ERS [----] @ConnectBiopharm will present two posters on Monday Sep [--] in Session [---] at the European Respiratory Society Congress [----] highlighting rademikibarts impact in moderate to severe and Type [--] asthma. Topics include biomarker-driven responses by eosinophils and FeNO plus rapid and sustained FEV1 improvements. Full Presentation Details Here: $CNTB $GSK $REGN $ARWR $MRK $VRTX $SNY $AMGN https://bit.ly/41B2jiG https://bit.ly/41B2jiG"
X Link 2025-09-04T12:40Z [----] followers, [---] engagements

"⚛ Greenwich LifeSciences $GLSI: A Quick Look at a Promising Phase III Breast Cancer Therapy @GreenwichLS is making major strides in the fight against breast cancer. Its lead immunotherapy candidate GLSI-100 is now in a global Phase III trial (FLAMINGO-01) spanning [---] sites across the U.S. and Europe targeting up to [---] HER2+ breast cancer patients. Why This Matters to Investors: Breakthrough Potential: Aims to reduce recurrence rates by over 80% outperforming current HER2 therapies. Robust Safety Profile: Supported by ongoing Data Safety Monitoring Board reviews with no changes required."
X Link 2025-09-09T13:40Z [----] followers, [---] engagements

"🎙 Connect Biopharma $CNTB: CEO Barry Quart Discusses Transformative Respiratory Pipeline In an exclusive new interview @ConnectBiopharm CEO Barry Quart shares insights into how the company is redefining treatment for asthma and COPD with its lead asset rademikibart: a next-gen monoclonal antibody showing best-in-class potential. Why This Matters for Investors: Massive Market Potential: Targeting diseases representing $5B in annual opportunity. Strong Clinical Backing: Global Phase [--] data shows rapid sustained efficacy and a strong safety profile. Strategic Leadership: U.S.-focused team with"
X Link 2025-09-10T13:00Z [----] followers, [---] engagements

"🎥 FatPipe $FATN CEO Interview: Inside a Profitable High-Margin Software Business Dont miss this exclusive conversation with Ragula Bhaskar PhD President & CEO of @FatPipe_Inc $FATN a leader in secure software-defined networking. Why Investors Should Watch: Positioned at the intersection of SD-WAN SASE and NMS: a $49B+ TAM by [----] 90%+ gross margins and a recurring revenue model Global footprint with over [----] enterprise customers Backed by patented tech and a pure-play focus on mission-critical infrastructure FatPipe is delivering results and scaling smart. Watch now: $FATN $AVGO $CSCO $ORCL"
X Link 2025-09-10T13:25Z [----] followers, [---] engagements

"🎙 Connect Biopharma $CNTB: CEO Barry Quart Discusses Transformative Respiratory Pipeline In an exclusive new interview @ConnectBiopharm CEO Barry Quart shares insights into how the company is redefining treatment for asthma and COPD with its lead asset rademikibart: a next-gen monoclonal antibody showing best-in-class potential. Why This Matters for Investors: Massive Market Potential: Targeting diseases representing $5B in annual opportunity. Strong Clinical Backing: Global Phase [--] data shows rapid sustained efficacy and a strong safety profile. Strategic Leadership: U.S.-focused team with"
X Link 2025-09-17T13:00Z [----] followers, [---] engagements

"🎙 Connect Biopharma $CNTB: CEO Barry Quart Discusses Transformative Respiratory Pipeline In an exclusive new interview @ConnectBiopharm CEO Barry Quart shares insights into how the company is redefining treatment for asthma and COPD with its lead asset rademikibart: a next-gen monoclonal antibody showing best-in-class potential. Why This Matters for Investors: Massive Market Potential: Targeting diseases representing $5B in annual opportunity. Strong Clinical Backing: Global Phase [--] data shows rapid sustained efficacy and a strong safety profile. Strategic Leadership: U.S.-focused team with"
X Link 2025-09-24T13:00Z [----] followers, 49.1K engagements

"💡 Connect Biopharma $CNTB Presents Promising Data for Rademikibart at ERS [----] Key Highlights: Lung Function Gains: Rapid and sustained FEV improvement up to [---] mL in patients with high Type [--] inflammation markers. Exacerbation Reduction: Up to 69% fewer asthma exacerbations in patients with elevated eosinophils or FeNO. Pipeline Momentum: Supports ongoing Seabreeze STAT Phase [--] studies in asthma and COPD with topline results expected 1H26. Why It Matters: Rademikibarts data reinforces its potential as a next-generation IL-4R antibody targeting moderate-to-severe asthma and COPD"
X Link 2025-09-29T14:33Z [----] followers, [---] engagements

"🎙 Connect Biopharma $CNTB: CEO Barry Quart Discusses Transformative Respiratory Pipeline In an exclusive new interview @ConnectBiopharm CEO Barry Quart shares insights into how the company is redefining treatment for asthma and COPD with its lead asset rademikibart: a next-gen monoclonal antibody showing best-in-class potential. Why This Matters for Investors: Massive Market Potential: Targeting diseases representing $5B in annual opportunity. Strong Clinical Backing: Global Phase [--] data shows rapid sustained efficacy and a strong safety profile. Strategic Leadership: U.S.-focused team with"
X Link 2025-10-01T13:00Z [----] followers, 53.2K engagements

"🎙 Connect Biopharma $CNTB: CEO Barry Quart Discusses Transformative Respiratory Pipeline In an exclusive new interview @ConnectBiopharm CEO Barry Quart shares insights into how the company is redefining treatment for asthma and COPD with its lead asset rademikibart: a next-gen monoclonal antibody showing best-in-class potential. Why This Matters for Investors: Massive Market Potential: Targeting diseases representing $5B in annual opportunity. Strong Clinical Backing: Global Phase [--] data shows rapid sustained efficacy and a strong safety profile. Strategic Leadership: U.S.-focused team with"
X Link 2025-10-08T13:00Z [----] followers, [---] engagements

"🎙 Connect Biopharma $CNTB: CEO Barry Quart Discusses Transformative Respiratory Pipeline In an exclusive new interview @ConnectBiopharm CEO Barry Quart shares insights into how the company is redefining treatment for asthma and COPD with its lead asset rademikibart: a next-gen monoclonal antibody showing best-in-class potential. Why This Matters for Investors: Massive Market Potential: Targeting diseases representing $5B in annual opportunity. Strong Clinical Backing: Global Phase [--] data shows rapid sustained efficacy and a strong safety profile. Strategic Leadership: U.S.-focused team with"
X Link 2025-10-15T13:00Z [----] followers, [---] engagements

"📣 Upcoming Webinar: Connect Biopharma $CNTB Targets Massive Respiratory Markets Join us Monday November [--] at 4:15 PM ET for a live investor webinar with Connect Biopharma advancing a next-gen therapy for acute asthma and COPD indications affecting millions. Why Attend Rademikibarts Phase 2b data shows rapid and sustained lung function improvement Addressing a $5B+ peak sales opportunity in asthma and COPD Upcoming topline data in 1H [----] from ongoing Phase [--] Seabreeze STAT trials Strong balance sheet with runway into [----] Dont miss insights on clinical progress commercial strategy and growth"
X Link 2025-10-20T14:44Z [----] followers, [---] engagements

"🎙 Connect Biopharma $CNTB: CEO Barry Quart Discusses Transformative Respiratory Pipeline In an exclusive new interview @ConnectBiopharm CEO Barry Quart shares insights into how the company is redefining treatment for asthma and COPD with its lead asset rademikibart: a next-gen monoclonal antibody showing best-in-class potential. Why This Matters for Investors: Massive Market Potential: Targeting diseases representing $5B in annual opportunity. Strong Clinical Backing: Global Phase [--] data shows rapid sustained efficacy and a strong safety profile. Strategic Leadership: U.S.-focused team with"
X Link 2025-10-22T13:00Z [----] followers, 42.7K engagements

"🗓 [--] Week Away: Connect Biopharma $CNTB Live Investor Webinar Learn how Rademikibart is positioned to disrupt the $5B+ respiratory market with best-in-class potential. Monday Nov. [--] 4:15 PM ET Register Here: $CNTB $GSK $REGN $ARWR $MRK $VRTX $SNY $AMGN https://redchip.news/4oo83Fh https://redchip.news/4oo83Fh"
X Link 2025-10-27T14:45Z [----] followers, [---] engagements

"🚨 Starting Soon Connect Biopharma $CNTB Investor Webinar begins in [--] mins. 🔗 Join live: $CNTB $GSK $REGN $ARWR $MRK $VRTX $SNY $AMGN https://redchip.news/4qeKEIj https://redchip.news/4qeKEIj"
X Link 2025-11-03T21:00Z [----] followers, [---] engagements

"RedChip Investor Webinar with Connect Biopharma (Nasdaq: CNTB) https://x.com/i/broadcasts/1vAxRQdpoRqJl https://x.com/i/broadcasts/1vAxRQdpoRqJl"
X Link 2025-11-03T21:13Z [----] followers, [---] engagements

"Join Connect Biopharma $CNTB's leadership for our investor webinar followed by a Q&A session: live now $CNTB $GSK $REGN $ARWR $MRK $VRTX $SNY $AMGN RedChip Investor Webinar with Connect Biopharma (Nasdaq: CNTB) https://t.co/9VAKNQ311C RedChip Investor Webinar with Connect Biopharma (Nasdaq: CNTB) https://t.co/9VAKNQ311C"
X Link 2025-11-03T21:30Z [----] followers, [---] engagements

"🎙 Connect Biopharma $CNTB: CEO Barry Quart Discusses Transformative Respiratory Pipeline In an exclusive new interview @ConnectBiopharm CEO Barry Quart shares insights into how the company is redefining treatment for asthma and COPD with its lead asset rademikibart: a next-gen monoclonal antibody showing best-in-class potential. Why This Matters for Investors: Massive Market Potential: Targeting diseases representing $5B in annual opportunity. Strong Clinical Backing: Global Phase [--] data shows rapid sustained efficacy and a strong safety profile. Strategic Leadership: U.S.-focused team with"
X Link 2025-11-05T14:00Z [----] followers, 47.3K engagements

"🎙 Connect Biopharma $CNTB: CEO Barry Quart Discusses Transformative Respiratory Pipeline In an exclusive new interview @ConnectBiopharm CEO Barry Quart shares insights into how the company is redefining treatment for asthma and COPD with its lead asset rademikibart: a next-gen monoclonal antibody showing best-in-class potential. Positioned for late-stage development and future commercialization $CNTB offers a compelling biotech growth story. Watch now: $CNTB $GSK $REGN $ARWR $MRK $VRTX $SNY $AMGN https://redchip.news/43hxikI https://redchip.news/43hxikI"
X Link 2025-11-12T14:00Z [----] followers, [---] engagements

"💡 Connect Biopharma $CNTB Reports Q3 Results Showcasing Continued Momentum and Upcoming Milestones Key Highlights: Clinical Progress: Recruitment ongoing in Phase [--] Seabreeze STAT trials for acute asthma and COPD exacerbations with topline data expected 1H [----]. Regulatory Milestone: Simceres New Drug Application for rademikibart in atopic dermatitis accepted by Chinas NMPA a critical step toward commercial entry in Greater Chinas 70M-patient AD market. Financial Strength: $54.8M in cash and equivalents funding operations into [----] providing a clear runway for clinical execution."
X Link 2025-11-12T15:09Z [----] followers, [---] engagements

"📢 Fox Business Varney & Co. highlights @NovaMinerals' landmark $43.4 million grant from the U.S. Department of War in an exclusive interview with $NVA CEO Chris Gerteisen. The grant enables Nova to establish Americas first fully integrated domestic antimony mining and refining operation a critical step toward reducing reliance on China for this strategically important critical material. With strong government backing world-class gold assets and a vertically integrated strategy $NVA is poised to become a key U.S. supplier to defense and industrial markets. Watch Varney & Co.'s full interview"
X Link 2025-11-12T21:34Z [----] followers, [----] engagements

"🎥 Nova Minerals: CEO Chris Gerteisen on Gold & Antimony Strategy @NovaMinerals $NVA is advancing its [---] sq. mile Estelle Project in Alaska already defining nearly 10Moz of gold and uncovering high-grade antimony: a critical mineral now in U.S. defense focus. Why It Matters: With gold and antimony both at record highs $NVA is uniquely positioned at the intersection of precious metals growth and critical U.S. supply chain security. Watch CEO Chris Gerteisens full interview for insights on strategy milestones and the road to production: $NVA $MP $PPTA $TECK $KGC $USGO $NG $THM $WRN $HL $GPH"
X Link 2025-11-28T15:25Z [----] followers, [---] engagements

"📢 Connect Biopharma $CNTB: Advancing the Only Biologic Aimed at Treating Acute Asthma Attacks In our latest interview CEO Dr. Barry Quart explains how rademikibart could become the first and only biologic positioned for use during acute asthma and COPD exacerbations a treatment area that has seen no innovation in more than [--] years. Watch our interview with Dr. Quart: $CNTB $GSK $REGN $ARWR $MRK $VRTX $SNY $AMGN https://redchip.news/43hxikI https://redchip.news/43hxikI"
X Link 2025-12-12T14:00Z [----] followers, [---] engagements

"🔔 Nova Minerals $NVA: Advancing U.S. Strategy in Critical Minerals and Gold Development @NovaMinerals $NVA is leading the U.S. race to secure antimony a mineral essential to defense and tech with a $43.4M award from the United States Department of War. Nova is building the only domestic military-grade antimony supply chain with production targeted by 2026/27. Watch Our [--] Sec $NVA Overview: $NVA $MP $PPTA $TECK $KGC $USGO $NG $THM $WRN $HL $GPH $NST $FVL $CTGO $XAU $XAUUSD https://redchip.news/4qb6eMP https://redchip.news/4qb6eMP"
X Link 2025-12-22T15:25Z [----] followers, [---] engagements

"📈 OBOOK Holdings $OWLS: Positioning for the Rise of AI-Driven Commerce OBOOK announced plans to adopt the x402 open payment standard introduced by Coinbase enabling merchants to accept payments initiated directly by AI agents. Through its OwlPay Checkout solutions the company aims to deliver the regulated merchant infrastructure needed to turn AI-initiated transactions into recognized revenue. As AI-driven commerce accelerates $OWLS is targeting the transaction and settlement layer where digital instructions become real revenue. Its licensed global payments infrastructure positions @OwlTing"
X Link 2026-01-09T18:36Z [----] followers, [---] engagements

"📌 OBOOK Holdings $OWLS Secures Nevada Money Transmitter License Expanding U.S. Coverage to [--] States The latest license strengthens @OwlTings ability to serve high-volume hospitality tourism and cross-border commerce in a key payments hub. The approval builds on OwlTings existing EU VASP license and Japan Bank API license with additional regulatory approvals in progress across Hong Kong Singapore and Latin America supporting broader enterprise onboarding and global payment flows. Read the full release: $OWLS $COIN $PYPL $SQ $NATL $MARA $RIOT $MSTR $NVDA https://redchip.news/4pInw3w"
X Link 2026-01-14T14:30Z [----] followers, [---] engagements

"📢 $AVL Initiates Updated PEA at Nechalacho Targeting Path to DFS @AvalonAdvanced has launched a refreshed Preliminary Economic Assessment for its Nechalacho Rare Earths Project incorporating updated processing engineering and cost assumptions. The study led by Wood Canada Limited is expected to be completed within approximately six months and expected to be followed by a Definitive Feasibility Study to support and advance financing offtake and partnership discussions. Read the full announcement: $AVL $AVLNF $MP $UUUU $ALB $USAR https://redchip.news/49oZZjg"
X Link 2026-01-15T15:12Z [----] followers, [---] engagements

"🪙 Blue Gold $BGL: Building a Gold-Backed Digital Asset for a Global Payment Ecosystem Hear directly from $BGL leadership at @RedChip's Fintech & DATS Virtual Investor Conference including a live presentation + Q&A. Blue Golds Standard Gold Coin (SGC) is designed as a 1:1 gold-backed digital token where each token represents one gram of vaulted physical gold. The long-term vision is a digital currency anchored by gold rather than fiat reserves. Standard Gold Coin is targeted to launch in Q1 [----] with early interest shown by 1M+ tokens pre-registered within days implying roughly $129M in"
X Link 2026-01-21T19:25Z [----] followers, 24.8K engagements

"⛓ From Ethereum Yield to MEV: The most sophisticated Ethereum play in public markets today @RedChip's Fintech and DATS Investor Conference brings crypto investors direct access to $BTCS' leadership on Feb 4th at 2:30 PM ET. Our live session will dive into how BTCS is an Ethereum-focused infrastructure company not simply a proxy for $ETH prices. BTCS is actively entering [----] with momentum supported by record growth expanding ecosystem relationships and a more diversified set of revenue-generating operations. Hear more about the continued internal development of Imperium leveraging its"
X Link 2026-01-27T13:33Z [----] followers, [---] engagements

"Learn more about First Phosphate & sign up for news alerts: $PHOS $FRSPF $MOS $NTR $VALE $IFOS $DAN $CXM https://redchip.news/4t1WzdK https://redchip.news/4t1WzdK"
X Link 2026-01-27T21:14Z [----] followers, [---] engagements

"📊 BTCS $BTCS: An Ethereum-First Public Blockchain Company In just [--] seconds see how @NasdaqBTCS is scaling Ethereum infrastructure with: Proprietary Builder+ platform driving block building revenue Validator node operations generating staking rewards A DeFi/TradFi flywheel designed to enhance shareholder value Watch our quick overview and discover why $BTCS is positioned as one of the most sophisticated public Ethereum plays. Overview Here: $BTCS $COIN $RIOT $HIVE $MARA $NVDA $ETH $SQ https://bit.ly/4gcdyEu https://bit.ly/4gcdyEu"
X Link 2026-01-28T13:40Z [----] followers, [---] engagements

"🐕 Brag House Holdings $TBH is building a new financial ecosystem anchored by payments infrastructure asset management and real-world asset tokenizationleveraging its exclusive partnership with the Dogecoin Foundation to drive institutional adoption. Hear directly from $TBH management at @RedChips February [--] Fintech & DATS Virtual Investor Conference. Register free: $TBH $DOGE $OWLS $ENLV $BNBX $BGL $BULL $OXBR $BTBT $BTCS $IPST $MMA https://redchip.news/4bRGTnd https://redchip.news/4bRGTnd"
X Link 2026-01-29T13:40Z [----] followers, 53K engagements

"Today at 4:15 PM ET: Live investor webinar with ProPhase Labs $PRPH hosted by CEO Ted Karkus Presentation + extended live Q&A for registrants. Register here: $PRPH $GSK $VXRT $ADAG $REGN $ARWR $MRK $VRTX $SNY $AMGN https://redchip.news/4sYsGuX https://redchip.news/4sYsGuX"
X Link 2026-02-03T13:33Z [----] followers, [---] engagements

"Starting in [--] minutes (4:15 PM ET): ProPhase Labs $PRPH live investor webinar with CEO Ted Karkus + extended Q&A. Register here: $PRPH $GSK $VXRT $ADAG $REGN $ARWR $MRK $VRTX $SNY $AMGN https://redchip.news/4q0Dnun https://redchip.news/4q0Dnun"
X Link 2026-02-03T21:00Z [----] followers, [---] engagements

"RedChip Investor Webinar with ProPhase Labs (OTC: PRPH) https://x.com/i/broadcasts/1ypJdqpnoQnxW https://x.com/i/broadcasts/1ypJdqpnoQnxW"
X Link 2026-02-03T21:27Z [----] followers, 31.2K engagements

"Learn more about $PRPH & sign up for news alerts: $PRPH $GSK $VXRT $ADAG $REGN $ARWR $MRK $VRTX $SNY $AMGN https://redchip.news/3ZjQfRo https://redchip.news/3ZjQfRo"
X Link 2026-02-03T21:32Z [----] followers, [---] engagements

"Join our live investor Q&A with ProPhase Labs: live now $PRPH $GSK $VXRT $ADAG $REGN $ARWR $MRK $VRTX $SNY $AMGN RedChip Investor Webinar with ProPhase Labs (OTC: PRPH) https://t.co/MWtJYRKuTI RedChip Investor Webinar with ProPhase Labs (OTC: PRPH) https://t.co/MWtJYRKuTI"
X Link 2026-02-03T21:32Z [----] followers, [---] engagements

"Questions Join our live Q&A $OWLS $ENLV $BNBX $BGL $BULL $OXBR $BTBT $TBH $DOGE $BTCS $IPST $MMA https://redchip.news/4kdxSXQ RedChip's Fintech & DATS Investor Conference: Modern Payments to Strategic Digital Asset Management https://t.co/V7ZNZXIeDO https://redchip.news/4kdxSXQ RedChip's Fintech & DATS Investor Conference: Modern Payments to Strategic Digital Asset Management https://t.co/V7ZNZXIeDO"
X Link 2026-02-04T15:33Z [----] followers, [---] engagements

"Money still moves slower than data. Stablecoins change thatand OBOOK Holdings (OwlTing Group; Nasdaq: $OWLS) is building the rails to make it work inside the financial system. Hear directly from the CEO on why @OwlTing Group is positioning itself as the backbone of next-gen global payments. 👉 Full article + interview: $OWLS $COIN $PYPL $SQ $NATL $MARA $RIOT $MSTR $NVDA https://redchip.news/3O3Gkgl https://redchip.news/3O3Gkgl"
X Link 2026-02-05T13:23Z [----] followers, 22.3K engagements

"⚡ First Phosphate (CSE: PHOS OTCQX: FRSPF): Investing in a Critical LFP Battery Supply Chain Bottleneck Lithium iron phosphate (LFP) batteries are projected to grow from $82B to $160B by [----] and high purity phosphate is a key input for this chemistry. See how @FirstPhosphate is positioning itself as a potential North American supplier of battery grade phosphate for the LFP market in our 30-second overview. $PHOS $FRSPF $MOS $NTR $VALE $IFOS $DAN $CXM https://redchip.news/4qhsi8e https://redchip.news/4qhsi8e"
X Link 2026-02-06T16:45Z [----] followers, [---] engagements

"📍 Today at 4:15 PM ET: Nexalin $NXL Live Investor Webinar Join CEO Mark White for a brief presentation + Q&A with registrants. Register Now: $NXL $VRTX $STIM $NMTC $LLY $AMGN $REGN $GILD $MRNA https://redchip.news/3O4uHWn https://redchip.news/3O4uHWn"
X Link 2026-02-11T14:35Z [----] followers, [---] engagements

"🚨 Starting in [--] minutes: Nexalin $NXL Live Investor Webinar + Q&A. Join Us: $NXL $VRTX $STIM $NMTC $LLY $AMGN $REGN $GILD $MRNA https://redchip.news/3YYsj64 https://redchip.news/3YYsj64"
X Link 2026-02-11T21:00Z [----] followers, [---] engagements

"Join our live investor Q&A with Nexalin: live now $NXL $VRTX $STIM $NMTC $LLY $AMGN $REGN $GILD $MRNA https://x.com/i/broadcasts/1dRKZaYNAovxB https://x.com/i/broadcasts/1dRKZaYNAovxB"
X Link 2026-02-11T21:19Z [----] followers, 50.4K engagements

"🎥 @ASPIsotopes: One-Minute Insight into a High-Impact Growth Story $ASPI is pioneering the next frontier of isotope production right as global demand surges in nuclear medicine quantum computing and clean energy. Backed by $60M+ in cash and a scalable business model $ASPI is now commercializing key isotopes like Ytterbium-176 and Carbon-14 under long-term supply agreements. Why This Matters for Investors Transition to Revenue: From R&D to commercialization in [----] Strategic Partnerships: Backed by TerraPower and South Africas Necsa Breakthrough Technology: Proprietary Aerodynamic and Quantum"
X Link 2026-02-12T13:15Z [----] followers, [---] engagements

"🧬 Regenerative medicine is rapidly advancing and Xtant Medical $XTNT is building its future on biologics designed to accelerate natural healing. $XTNT's proprietary biologics are engineered to preserve the bodys own growth factors support tissue repair and meet rising demand for next-gen regenerative solutions. With 19% revenue growth strong margins and guidance raised above $130M the biology is driving the business. Watch our 30-second overview: $XTNT $JNJ $ABBV $MRK $AZN $LLY $PFE $BMY $NVS $AXSM $XENE $USPH $BVS https://redchip.news/440smkB https://redchip.news/440smkB"
X Link 2026-02-13T15:15Z [----] followers, [--] engagements

"📢 Nexalin Technology $NXL: Frequency-Based Brain Stimulation + Military TBI/PTSD Opportunity In our recent interview CEO Mark White explains why Nexalins approach stands out: a whole-brain stimulation technique that uses frequencies not electrical energy to talk to the brain in its native language with 75-90% efficacy reported in clinically published trials. With Nexalin scaling an at-home neuromodulation platform while advancing PTSD/TBI programs it opens a potentially significant path to adoption in high-need populations and broader commercial markets. Watch our full interview here: $NXL"
X Link 2026-02-16T15:30Z [----] followers, 15.4K engagements

"🎥 @NioCorp $NB: [--] Seconds Investors Should See Construction-ready U.S. critical minerals project with all major permits secured Offtake visibility: 75% of planned niobium output under long-term agreements plus the largest scandium sales deal on record Financing momentum: U.S. EXIM processing about $800M in debt with potential $400M in additional ECA support and a Department of War grant of up to $10M Scandium strengthens aluminum and niobium strengthens steel: vital for aerospace and defense applications where lighter stronger alloys drive performance. Watch our 30-second overview: $NB $MP"
X Link 2026-02-16T15:35Z [----] followers, [---] engagements

"⛏ Avalon Advanced Materials ($AVL $AVLNF): Lake Superior Lithium Moves Into Feasibility Study Engineering @AvalonAdvanced engaged Rachel Bridge (CEO Laira Consulting Services) as an interim consultant to coordinate with Nordmin Engineering as the Lake Superior Lithium (LSLi) Project advances from the [----] PEA into the Feasibility Study phase. This adds near-term execution support while Avalon hires a full-time Project Director and helps keep feasibility engineering moving on schedule. The feasibility study is aimed at tightening the projects cost estimates and build plan while identifying and"
X Link 2026-02-17T17:55Z [----] followers, [---] engagements

"🌐 Greenwich LifeSciences $GLSI: Expanding FLAMINGO-01 Phase III Trial into France @GreenwichLS has partnered with Unicancer the largest academic breast cancer research network in France to activate clinical sites for FLAMINGO-01. This Phase III trial evaluates GLSI-100 an innovative immunotherapy aiming to prevent HER2+ breast cancer recurrences. 💡 Why This Matters to Investors: - Global Expansion: [--] French sites join the trial broadening access to GLSI-100 across major European cancer centers. - Market Potential: France reported [-----] new breast cancer cases in [----] underscoring the"
X Link 2025-01-13T15:16Z [----] followers, [---] engagements

"📢 Greenwich LifeSciences $GLSI: Expands Phase III FLAMINGO-01 Trial with GBG in Germany 🌍 Strategic Partnership: @GreenwichLS has joined forces with GBG (German Breast Group) the largest breast cancer research network in Germany to advance Phase III breast cancer trial. Approximately [--] clinical sites are participating with most already approved by German authorities marking a major step forward for the trial. 💡 Why It Matters for Investors: Phase III Momentum: FLAMINGO-01 evaluates GLSI-100 a potential breakthrough immunotherapy to prevent HER2+ breast cancer recurrences. Global"
X Link 2025-01-14T13:09Z [----] followers, [----] engagements

"📢 Greenwich LifeSciences $GLSI: Progress on Commercial Manufacturing of GP2 @GreenwichLS has achieved key milestones in the commercial manufacturing of GP2 the active ingredient in GLSI-100 aimed at preventing breast cancer recurrences. 💡 Why This Matters for Investors: - Manufacturing Milestone: First commercial GP2 lots produced in [----] sufficient for [------] doses with additional vials manufactured in [----] for regulatory review and potential clinical use. - Regulatory Pathway: Manufacturing data is critical for filing a Biologics License Application (BLA) in the U.S. and Europe"
X Link 2025-01-22T13:58Z [----] followers, [----] engagements

"📢 Greenwich LifeSciences $GLSI: Harvard and Johns Hopkins Join FLAMINGO-01 Clinical Trial 🌟 @GreenwichLS has added @Harvard University and @JohnsHopkins University as new clinical sites for FLAMINGO-01 a Phase III trial evaluating GLSI-100 an immunotherapy aimed at preventing HER2-positive breast cancer recurrences. 💡 Why This Matters to Investors: Elite Leadership: Dr. Laura Spring (Harvard) and Dr. Cesar Santa-Maria (Johns Hopkins) join $GLSI's Steering Committee bringing renowned expertise in breast cancer immunotherapy and clinical trial innovation. Strategic Growth: The trial now"
X Link 2025-01-23T13:43Z [----] followers, [---] engagements

"📣 Greenwich LifeSciences $GLSI: FLAMINGO-01 Phase III Trial Expands to Poland @GreenwichLS activates clinical sites in Poland for FLAMINGO-01 a Phase III trial evaluating GLSI-100 as an immunotherapy to prevent breast cancer recurrences. 🔬 Why This Matters to Investors: 🌍 Global Reach: [---] sites in Poland approved marking strategic European expansion. 🎗 High Demand: Poland reports 24500+ new breast cancer cases annually addressing a critical need. 🤝 Strong Collaboration: Led by Dr. Piotr Wysocki a prominent oncology expert with an extensive research network. 🏥 Expansion may also benefit"
X Link 2025-01-27T13:39Z [----] followers, [---] engagements

"📢 Greenwich LifeSciences $GLSI Expands Phase III FLAMINGO-01 Trial in Europe @GreenwichLS has received regulatory approval to add [--] new trial sites across Spain Germany and Poland strengthening the late-stage FLAMINGO-01 study of GLSI-100 an immunotherapy designed to prevent HER2+ breast cancer recurrences. 🌍 Why This Matters for Investors: ✅ Expanded Trial Reach: Regulatory clearance now enables up to 110-115 active sites in Europe. ✅ Strong Investigator Interest: Additional sites in Ireland Romania and beyond are under consideration. ✅ Global Momentum: Nearly [---] sites worldwide are now"
X Link 2025-01-29T14:00Z [----] followers, [---] engagements

"📢 OS Therapies $OSTX Expands Pipeline with Key Immuno-Oncology Acquisition @OSTherapies has entered an asset purchase agreement with Ayala Pharmaceuticals $AYLA securing full ownership of its Listeria monocytogenes-based immunotherapy platform. This strategic move adds Phase [--] lung cancer and Phase [--] prostate cancer programs while enhancing the companys lead asset OST-HER2 for osteosarcoma. 💡 Why This Matters for Investors: ✅ Stronger Clinical Pipeline Expanding into high-growth lung and prostate cancer markets ✅ Financial Benefits Eliminates milestone payments reduces royalties and boosts"
X Link 2025-01-29T15:16Z [----] followers, [---] engagements

"📢 Greenwich LifeSciences $GLSI Updates FLAMINGO-01 Phase III Trial with Open Label HLA Data Preliminary findings from analyzing open-label HLA data from its Phase III trial reveal that 46% of screened patients carry at least one HLA-A02 allele aligning with expectations and supporting the study's sample size estimates. 🔬 Why This Matters to Investors: ✅ Expanded Patient Insights: The open-label arm now increased to [---] patients may provide critical efficacy and immune response data in non-HLA-A02 populations. ✅ Enhanced Trial Design: The ability to assess various HLA-A combinations"
X Link 2025-02-10T13:41Z [----] followers, [---] engagements

"🚀 GreenPower Motor Company $GP: Live Investor Webinar on Feb. [--] @GreenPowerBus a leader in zero-emission medium and heavy-duty electric vehicles invites investors to an exclusive webinar on Wednesday Feb. 26th at 4:15 PM ET. 💡 Why Investors Should Tune In: 📈 Strong Q3 Results $7.2M in revenue up 35% QoQ with rising gross profits. 🏭 Manufacturing Expansion Increasing production at the West Virginia and California facilities to meet demand. 💰 Financial Strength $12.8M in working capital and $5M in available funding to fuel growth. 🔗 Register now to gain insights into GreenPowers growth"
X Link 2025-02-19T21:05Z [----] followers, [---] engagements

"1 Day Until GreenPower Motors $GP Investor Webinar 🚀 Join $GP's live investor webinar tomorrow Feb. [--] at 4:15 PM ET 📢 Hear from leadership on: 📈 Q3 Growth $7.2M revenue (+35% QoQ) with improving profitability. 🏭 Production Expansion Scaling EV manufacturing in West Virginia & California. 💡 Future Outlook How $GP is positioned for long-term success in zero-emission transportation. 🔗 Dont miss this opportunity Register now: $GP $TSLA $BYD $NIO $LI $RIVN $LCID #EV #Investing #GreenEnergy #GP #ZeroEmissions #StockMarket"
X Link 2025-02-25T19:52Z [----] followers, [---] engagements

"🚍 GreenPower Motor $GP: Catch Up on the Latest Investor Webinar $GP's leadership just wrapped up an insightful investor webinar discussing the companys strong growth operational expansion and the growing demand for its purpose-built commercial EVs. 📊 Key Takeaways: ✅ 35% Revenue Growth: $7.2M in Q3 revenue driven by rising demand for $GP's EV lineup. ✅ Scaling Production: West Virginia plant ramping up BEAST school bus output to meet fleet electrification needs. ✅ Strategic Expansion: Consolidating California operations to enhance efficiency and cost savings. ✅ Strong Competitive Position:"
X Link 2025-02-28T19:36Z [----] followers, [---] engagements

"🔒 Greenwich LifeSciences $GLSI Extends Insider Lock-Up Through March [----] 💡 Why This Matters for Investors: ✅ Long-Term Commitment: Reinforces leaderships confidence in the companys future and aligns insider interests with shareholders. ✅ Share Stability: Reduces potential selling pressure as GLSI advances its pivotal Phase III trial (FLAMINGO-01) for breast cancer recurrence prevention. ✅ Strong Governance: Lock-up restrictions beyond typical timelines underscore trust in the strategic value of GLSI-100. 📄 $GLSI $PFE $LLY $JNJ #RedChip #RedChat #GreenwichLS #BreastCancer #InsiderOwnership"
X Link 2025-03-27T13:04Z [----] followers, [---] engagements

"🧬 Greenwich LifeSciences $GLSI: Immune Response Data Supports $10B Breast Cancer Market Opportunity New Phase [--] FLAMINGO-01 data shows robust immune activation in both HLA-A*02 and non-HLA patientspotentially doubling the target population for GLSI-100. 📈 Key Takeaways: Immune response grows with dosingmirroring successful Phase 2b results New patent claims expand addressable market to 88K patients/year in US/EU Potential market: $810B/year with pricing comparable to Kadcyla/Enhertu CEO eyes trial expansion for dual approvals to accelerate market entry 📄 $GLSI $PFE $LLY $JNJ #RedChip"
X Link 2025-04-02T13:21Z [----] followers, 15.1K engagements

"📢 Greenwich LifeSciences $GLSI: Global Site Expansion & Record Screening Drive Phase [--] Momentum FLAMINGO-01 the pivotal trial for GLSI-100 in HER2+ breast cancer now spans [---] active sites across the US & EUon track for 150+ global sites in [----]. 💡 Why Investors Should Care ✅ Record Interest: Q1 screening hits all-time high (150+ patients) ✅ Regulatory Tailwind: Expanded non-HLA arm may enable dual approvals ✅ Commercial Prep: Manufacturing IP and distribution strategies advancing in parallel ✅ Elite Network: Trial backed by top cancer centers incl. @UCSF Baylor @Stanford Johns Hopkins"
X Link 2025-04-03T12:51Z [----] followers, [---] engagements

"🚀 FatPipe Inc. $FATN Closes $4M Nasdaq IPO FatPipe a pioneer in secure SD-WAN solutions has officially closed its IPO and commenced trading on the Nasdaq under the ticker FATN on April [--]. 💡 Why This Matters for Investors: - $4M in Gross Proceeds: Capital will support growth initiatives and strengthen the balance sheet. - Listed on Nasdaq: Enhances visibility and credibility as $FATN scales its global SD-WAN and cybersecurity solutions. - Expansive Market Opportunity: Serves a broad client baseenterprises government and service providerswith robust failover-proof network infrastructure. 📄"
X Link 2025-04-10T13:13Z [----] followers, 21.7K engagements

"📢 Greenwich LifeSciences $GLSI to Host Investor Webinar on Advancing Breast Cancer Immunotherapy @GreenwichLS invites investors to a live webinar on Tuesday April [--] at 4:15 PM EST to discuss the ongoing development of GLSI-100 an immunotherapy designed to reduce breast cancer recurrence in HER2/neu-positive patients. 💡 Why Investors Should Tune In: 🔬 Promising Phase IIb Results: Over 80% reduction in recurrence among HER2 3+ patients after [--] years of follow-up with no serious adverse events reported. 🧪 Phase III Trial in Progress: The global FLAMINGO-01 study spans [---] clinical sites"
X Link 2025-04-17T17:49Z [----] followers, [---] engagements

"📢 Greenwich LifeSciences $GLSI: Investor Webinar Set to Spotlight FLAMINGO-01 Phase III Progress @GreenwichLS will host a key Investor Webinar next Tuesday at 4:15PM EST offering an in-depth global update on its Phase III clinical trial FLAMINGO-01. 💡 Why This Matters to Investors: 🔬 Advancing Toward Commercialization: Early data from both HLA-A02 and non-HLA-A02 patient groups show promising immune response trends expanding the trials potential pathways to approval. 🌍 Global Expansion: With over [---] active sites across the U.S. and EUand plans to exceed 150the trial is now one of the"
X Link 2025-04-22T18:56Z [----] followers, [---] engagements

"📣 Reminder: Greenwich LifeSciences $GLSI Investor Webinar Tomorrow at 4:15PM EST Don't miss Greenwich LifeSciences' important investor webinar highlighting the latest global progress in the FLAMINGO-01 Phase III trial. 💡 Why Investors Should Tune In: ✅ Promising Preliminary Data: Early immune response results trending positively across multiple patient groups. ✅ Expanded Global Reach: [---] active sites across the U.S. and Europe with more to come. ✅ Strategic Insights: Updates on commercialization pathways regulatory strategies and patent life extension plans for GLSI-100. 🎯 With GLSI-100"
X Link 2025-04-28T17:59Z [----] followers, [---] engagements

"🚨 Today at 4:15 PM EST: Greenwich LifeSciences $GLSI Investor Webinar Join todays investor webinar to hear the latest on the FLAMINGO-01 Phase III trial $GLSI's lead program evaluating GLSI-100 for preventing HER2+ breast cancer recurrence. 💡 Key Topics for Investors: 📊 Trial Momentum: Over [---] active clinical sites across the U.S. and EU with plans to exceed [---]. 🧬 Promising Data: Positive immune response trends in both HLA-A02 and non-HLA-A02 patient groups. 🛠 Commercial Strategy: Insights into regulatory progress manufacturing and potential for dual approval pathways. 🌍 With global"
X Link 2025-04-29T13:33Z [----] followers, [---] engagements

"📣 FatPipe $FATN Rings Nasdaq Bell to Mark New Chapter in Global Expansion @FatPipe_Inc a pioneer in SD-WAN and secure enterprise networking will ring the @Nasdaq Closing Bell on May [--] to commemorate its recent public listing and accelerating global footprint. 💡 Why This Matters to Investors: - Public Listing Milestone: Highlights $FATN's evolution from a private innovator to a Nasdaq-listed issuer. - Proven Market Traction: Trusted by 2500+ enterprise customers with a strong presence in the U.S. and India. - Global Growth Strategy: Actively expanding across Southeast Asia and Mexico"
X Link 2025-04-30T14:27Z [----] followers, [---] engagements

"🚍 GreenPower Motor Company $GP: Accelerating EPA-Funded EV School Bus Deployments in West Virginia @GreenPowerBus has delivered [--] all-electric BEAST school buses to its West Virginia dealer for use in Grant County funded under Round [--] of the EPA's Clean School Bus Program. 💡 Why This Matters to Investors: - EPA-Backed Growth: Second delivery under the federal program in just four months signaling momentum in grant-driven sales. - Growing State Presence: [--] $GP buses now deployed across WVnearly half of total orders placed statewide. - Product Differentiation: The BEAST is a purpose-built"
X Link 2025-05-05T13:36Z [----] followers, [---] engagements

"📣 FatPipe $FATN: Closing Bell Ceremony Marks Public Market Momentum On Friday @FatPipe_Inc capped off a pivotal week by officially ringing the @Nasdaq Closing Bell celebrating its recent listing and accelerating expansion in global enterprise networking markets. 💡 Why This Matters to Investors: - Market Debut Cemented: The bell-ringing event underscores $FATN's transition into a publicly traded company with global ambitions. - Strong Customer Base: Serving 2500+ enterprises with patented SD-WAN and failover tech that solves real-world connectivity issues. - Expansion Underway: Momentum"
X Link 2025-05-05T20:52Z [----] followers, [---] engagements

"📽 Greenwich LifeSciences $GLSI: A Quick Look at a Promising Phase III Breast Cancer Therapy @GreenwichLS is making major strides in the fight against breast cancer. Its lead immunotherapy candidate GLSI-100 is now in a global Phase III trial (FLAMINGO-01) spanning [---] sites across the U.S. and Europe targeting up to [---] HER2+ breast cancer patients. 💡 Why This Matters to Investors: - Breakthrough Potential: Aims to reduce recurrence rates by over 50% outperforming current HER2 therapies. - Robust Safety Profile: Supported by ongoing Data Safety Monitoring Board reviews with no changes"
X Link 2025-05-06T13:35Z [----] followers, [---] engagements

"🎙 Must-Watch Interview: Fraser Atkinson CEO of GreenPower Motor $GP Talks EV Strategy & Growth $GP is driving the electrification of transportation with a purpose-built all-electric lineup of buses and trucks. With 900+ zero-emission vehicles built and $90M+ in revenue generated over the past three years the company is capitalizing on strong regulatory tailwinds and growing demand for clean transit solutions. 💡 Why Investors Should Tune In: - Undervalued Opportunity: Trades at 1x TTM saleswell below peers like Workhorse $WKHS and Nikola. - Profitability Edge: Only peer with positive gross"
X Link 2025-05-09T13:40Z [----] followers, [---] engagements

"🚀 FatPipe $FATN Strengthens Leadership to Drive Global Expansion Post-Nasdaq Listing 👀 @FatPipe_Inc $FATN a pioneer in secure SD-WAN and enterprise connectivity has announced key executive appointments to accelerate its next phase of growth. This move follows its recent @Nasdaq listing and supports expansion efforts across the U.S. India Southeast Asia and Mexico. 💡 Why This Matters for Investors: - Executive Firepower: New hires bring leadership experience from industry giants like AT&T $T and Reliance Datacomm overseeing sales teams generating $600M+ and $700M+ in revenue. - Market"
X Link 2025-05-09T18:58Z [----] followers, [---] engagements

"🚀 FatPipe Inc. $FATN Launches VeloCloud Replacement Program to Capture Legacy SD-WAN Market @FatPipe_Inc has introduced a strategic VeloCloud Replacement Program enabling enterprises to seamlessly upgrade from first-gen SD-WAN to $FATN's secure cloud-native high-performance platform. 💡 Why This Matters for Investors: - Market Expansion: Tapping into a global legacy SD-WAN base amid a market projected to exceed $7B by [----]. - Customer Acquisition & Recurring Revenue: Boosts new client onboarding with managed services and long-term licensing. - Zero-Cost Migration & Trade-In Incentives:"
X Link 2025-05-14T15:57Z [----] followers, [---] engagements

"📢 Investor Webinar Alert: Discover the Next Rule-of-40 Software WinnerFatPipe Networks $FATN Join us for an exclusive investor webinar featuring @FatPipe_Inc a profitable high-margin enterprise networking company at the forefront of SD-WAN SASE and NMS markets. 💡 Why Attend: - $5.2M in net income on $18.7M TTM revenue (28% net margin) - 90%+ gross margins and strong recurring revenue - Serving 2500+ customers in sectors like finance healthcare and government 🎯 Positioned for growth in a $49B+ TAM by [----]. 📍 Reserve your spot now: 🔗 #FATN #InvestorWebinar #EnterpriseTech #SoftwareStocks"
X Link 2025-05-14T18:40Z [----] followers, [---] engagements

"🎥 FatPipe $FATN CEO Interview: Inside a Profitable High-Margin Software Business Dont miss this exclusive conversation with Ragula Bhaskar PhD President & CEO of @FatPipe_Inc $FATN a leader in secure software-defined networking. 💡 Why Investors Should Watch: Positioned at the intersection of SD-WAN SASE and NMSa $49B+ TAM by [----] 90%+ gross margins and a recurring revenue model Global footprint with over [----] enterprise customers 🔒 Backed by patented tech and a pure-play focus on mission-critical infrastructure FatPipe is delivering results and scaling smart. 📺 Watch Now and hear how"
X Link 2025-05-21T13:25Z [----] followers, [---] engagements

"📢 Investor Webinar Alert: FatPipe Networks $FATN Unifying Securing and Optimizing Global Connectivity Join us Wednesday May [--] at 4:15 PM ET to hear how @FatPipe_Inc is capitalizing on the $49B+ SD-WAN SASE and NMS markets. 💡 Why Investors Should Attend: - Strong Profitability: 27.7% net margin and 35% adj. EBITDA margin. - Recurring Revenue Model: 90%+ gross margins with subscription-based software. - Expanding Global Reach: Serving 2500+ enterprise customers across key sectors. Get insights on $FATN's growth strategy and market positioning in enterprise networking. 🔗 Reserve Your Spot"
X Link 2025-05-21T14:27Z [----] followers, [---] engagements

"🚨 Reminder: FatPipe Networks $FATN Investor Webinar TOMORROW at 4:15 PM ET Dont miss your chance to hear directly from leadership on how @FatPipe_Inc is driving secure high-margin growth in the $49B+ enterprise networking market. Key Takeaways Youll Learn: - Strong Profitability: 27.7% net margin and 35% adj. EBITDA margin. - Recurring Revenue Model: 90%+ gross margins with subscription-based software. - Expanding Global Reach: Serving 2500+ enterprise customers across key sectors. 📅 May [--] 4:15 PM ET 🔗 Register Here: $FATN $CSCO $ORCL $HPE $FTNT #FinancialNews #SoftwareStocks #TechGrowth"
X Link 2025-05-27T16:35Z [----] followers, [---] engagements

"🎥 FatPipe $FATN CEO Interview: Inside a Profitable High-Margin Software Business Dont miss this exclusive conversation with Ragula Bhaskar PhD President & CEO of @FatPipe_Inc $FATN a leader in secure software-defined networking. 💡 Why Investors Should Watch: Positioned at the intersection of SD-WAN SASE and NMSa $49B+ TAM by [----] 90%+ gross margins and a recurring revenue model Global footprint with over [----] enterprise customers 🔒 Backed by patented tech and a pure-play focus on mission-critical infrastructure FatPipe is delivering results and scaling smart. 📺 Watch Now and hear how"
X Link 2025-05-28T13:25Z [----] followers, [---] engagements

"Going Live Today at 4:15 PM ET: FatPipe Networks $FATN Investor Webinar Join us to explore how @FatPipe_Incs subscription-based software 27.7% net margin and patented networking solutions position it to scale in the booming SD-WAN SASE and NMS markets. Why Join ✅ Hear managements growth vision ✅ Understand $FATN's profitability edge ✅ Learn about customer expansion opportunities Dont miss this opportunity to engage with one of the most capital-efficient small-cap tech players on the @Nasdaq. 🔗 Join the Webinar Here: $FATN $CSCO $ORCL $HPE $FTNT #InvestorWebinar #TechInvesting"
X Link 2025-05-28T15:27Z [----] followers, [---] engagements

"🎥 FatPipe $FATN CEO Interview: Inside a Profitable High-Margin Software Business Dont miss this exclusive conversation with Ragula Bhaskar PhD President & CEO of @FatPipe_Inc $FATN a leader in secure software-defined networking. 💡 Why Investors Should Watch: Positioned at the intersection of SD-WAN SASE and NMSa $49B+ TAM by [----] 90%+ gross margins and a recurring revenue model Global footprint with over [----] enterprise customers 🔒 Backed by patented tech and a pure-play focus on mission-critical infrastructure FatPipe is delivering results and scaling smart. 📺 Watch Now and hear how"
X Link 2025-06-04T13:25Z [----] followers, [---] engagements

"🎥 FatPipe $FATN CEO Interview: Inside a Profitable High-Margin Software Business Dont miss this exclusive conversation with Ragula Bhaskar PhD President & CEO of @FatPipe_Inc $FATN a leader in secure software-defined networking. 💡 Why Investors Should Watch: Positioned at the intersection of SD-WAN SASE and NMSa $49B+ TAM by [----] 90%+ gross margins and a recurring revenue model Global footprint with over [----] enterprise customers 🔒 Backed by patented tech and a pure-play focus on mission-critical infrastructure FatPipe is delivering results and scaling smart. 📺 Watch Now and hear how"
X Link 2025-06-11T13:25Z [----] followers, [---] engagements

"📺 Must-Watch: FatPipe Inc's CEO LIVE on Schwab TV. @FatPipe_Inc $FATN a leader in enterprise-grade network monitoring solutions is gaining traction in a $49B+ market with over [----] customers 90% gross margins and over 27% net margin beating SaaS benchmarks. 💡 Why Investors Should Tune In: - High-Margin Growth: 90%+ gross margins 35% adjusted EBITDA with sticky recurring revenue. - Massive TAM: Positioned in a $49B+ market across cloud hybrid and on-premise networking. - Scalable Model: Subscription-based revenue with strong IP (13 patents) with global reach. - CEO Insights: Get direct"
X Link 2025-06-11T20:28Z [----] followers, [---] engagements

"🎥 FatPipe $FATN CEO Interview: Inside a Profitable High-Margin Software Business Dont miss this exclusive conversation with Ragula Bhaskar PhD President & CEO of @FatPipe_Inc $FATN a leader in secure software-defined networking. 💡 Why Investors Should Watch: Positioned at the intersection of SD-WAN SASE and NMSa $49B+ TAM by [----] 90%+ gross margins and a recurring revenue model Global footprint with over [----] enterprise customers 🔒 Backed by patented tech and a pure-play focus on mission-critical infrastructure FatPipe is delivering results and scaling smart. 📺 Watch Now and hear how"
X Link 2025-06-18T13:25Z [----] followers, [---] engagements

"📽 Greenwich LifeSciences $GLSI: A Quick Look at a Promising Phase III Breast Cancer Therapy @GreenwichLS is making major strides in the fight against breast cancer. Its lead immunotherapy candidate GLSI-100 is now in a global Phase III trial (FLAMINGO-01) spanning [---] sites across the U.S. and Europe targeting up to [---] HER2+ breast cancer patients. 💡 Why This Matters to Investors: - Breakthrough Potential: Aims to reduce recurrence rates by over 80% outperforming current HER2 therapies. - Robust Safety Profile: Supported by ongoing Data Safety Monitoring Board reviews with no changes"
X Link 2025-06-25T13:20Z [----] followers, [---] engagements

"🎥 FatPipe $FATN CEO Interview: Inside a Profitable High-Margin Software Business Dont miss this exclusive conversation with Ragula Bhaskar PhD President & CEO of @FatPipe_Inc $FATN a leader in secure software-defined networking. 💡 Why Investors Should Watch: Positioned at the intersection of SD-WAN SASE and NMS: a $49B+ TAM by [----] 90%+ gross margins and a recurring revenue model Global footprint with over [----] enterprise customers 🔒 Backed by patented tech and a pure-play focus on mission-critical infrastructure FatPipe is delivering results and scaling smart. 📺 Watch Now and hear how"
X Link 2025-06-25T13:25Z [----] followers, [---] engagements

"🏆 FatPipe $FATN: Total Security [---] Wins [----] MSP Today Product of the Year @FatPipe_Inc's flagship cybersecurity solution Total Security [---] has earned top honors from TMCs MSP Today for its innovation and business impactvalidating its value to managed service providers and enterprise clients. 🔐 Why It Matters for Investors: - Industry Recognition: Reinforces $FATN's leadership in secure intelligent SD-WAN solutions. - Market Relevance: Addresses growing enterprise demand for integrated cybersecurity across hybrid cloud and on-premise environments. - Expanding Market: SD-WAN projected to"
X Link 2025-06-25T15:57Z [----] followers, [---] engagements

"📈 FatPipe Inc. $FATN Joins Russell 3000E and Russell Microcap Indexes: Expanding Visibility Among Institutional Investors @FatPipe_Inc has been added to the Russell 3000E and Russell Microcap Indexes following the [----] annual reconstitution. This milestone enhances the companys profile among fund managers and institutional investors tracking $10.6 trillion in assets. 💡 Why This Matters for Investors: - Increased Exposure: Inclusion in widely tracked indexes can attract new investment flows from index funds and institutional portfolios. - Market Recognition: Reflects $FATN's growing market"
X Link 2025-06-30T13:53Z [----] followers, [---] engagements

"📽 Greenwich LifeSciences $GLSI: A Quick Look at a Promising Phase III Breast Cancer Therapy @GreenwichLS is making major strides in the fight against breast cancer. Its lead immunotherapy candidate GLSI-100 is now in a global Phase III trial (FLAMINGO-01) spanning [---] sites across the U.S. and Europe targeting up to [---] HER2+ breast cancer patients. 💡 Why This Matters to Investors: - Breakthrough Potential: Aims to reduce recurrence rates by over 80% outperforming current HER2 therapies. - Robust Safety Profile: Supported by ongoing Data Safety Monitoring Board reviews with no changes"
X Link 2025-07-01T13:40Z [----] followers, [---] engagements

"🎥 FatPipe $FATN CEO Interview: Inside a Profitable High-Margin Software Business Dont miss this exclusive conversation with Ragula Bhaskar PhD President & CEO of @FatPipe_Inc $FATN a leader in secure software-defined networking. 💡 Why Investors Should Watch: Positioned at the intersection of SD-WAN SASE and NMS: a $49B+ TAM by [----] 90%+ gross margins and a recurring revenue model Global footprint with over [----] enterprise customers 🔒 Backed by patented tech and a pure-play focus on mission-critical infrastructure FatPipe is delivering results and scaling smart. 📺 Watch Now and hear how"
X Link 2025-07-02T13:25Z [----] followers, [---] engagements

"📽 Greenwich LifeSciences $GLSI: A Quick Look at a Promising Phase III Breast Cancer Therapy @GreenwichLS is making major strides in the fight against breast cancer. Its lead immunotherapy candidate GLSI-100 is now in a global Phase III trial (FLAMINGO-01) spanning [---] sites across the U.S. and Europe targeting up to [---] HER2+ breast cancer patients. 💡 Why This Matters to Investors: - Breakthrough Potential: Aims to reduce recurrence rates by over 80% outperforming current HER2 therapies. - Robust Safety Profile: Supported by ongoing Data Safety Monitoring Board reviews with no changes"
X Link 2025-07-08T13:40Z [----] followers, [---] engagements

"🎥 FatPipe $FATN CEO Interview: Inside a Profitable High-Margin Software Business Dont miss this exclusive conversation with Ragula Bhaskar PhD President & CEO of @FatPipe_Inc $FATN a leader in secure software-defined networking. 💡 Why Investors Should Watch: Positioned at the intersection of SD-WAN SASE and NMS: a $49B+ TAM by [----] 90%+ gross margins and a recurring revenue model Global footprint with over [----] enterprise customers 🔒 Backed by patented tech and a pure-play focus on mission-critical infrastructure FatPipe is delivering results and scaling smart. 📺 Watch Now and hear how"
X Link 2025-07-09T13:25Z [----] followers, [---] engagements

"📽 Greenwich LifeSciences $GLSI: A Quick Look at a Promising Phase III Breast Cancer Therapy @GreenwichLS is making major strides in the fight against breast cancer. Its lead immunotherapy candidate GLSI-100 is now in a global Phase III trial (FLAMINGO-01) spanning [---] sites across the U.S. and Europe targeting up to [---] HER2+ breast cancer patients. 💡 Why This Matters to Investors: - Breakthrough Potential: Aims to reduce recurrence rates by over 80% outperforming current HER2 therapies. - Robust Safety Profile: Supported by ongoing Data Safety Monitoring Board reviews with no changes"
X Link 2025-07-15T13:40Z [----] followers, [----] engagements

"🎥 FatPipe $FATN CEO Interview: Inside a Profitable High-Margin Software Business Dont miss this exclusive conversation with Ragula Bhaskar PhD President & CEO of @FatPipe_Inc $FATN a leader in secure software-defined networking. 💡 Why Investors Should Watch: Positioned at the intersection of SD-WAN SASE and NMS: a $49B+ TAM by [----] 90%+ gross margins and a recurring revenue model Global footprint with over [----] enterprise customers 🔒 Backed by patented tech and a pure-play focus on mission-critical infrastructure FatPipe is delivering results and scaling smart. 📺 Watch Now and hear how"
X Link 2025-07-16T13:25Z [----] followers, [---] engagements

"Pop Mart the $40B collectibles giant behind Labudu sees profit soar 350%. Could $AENT's Handmade by Robots be the next craze 🔗 $AENT $PMRTY $FNKO $SONY $DIS $NTDOY https://bbc.in/4eVDbbY https://bbc.in/4eVDbbY"
X Link 2025-07-17T12:58Z [----] followers, [---] engagements

"⚛ Greenwich LifeSciences $GLSI: A Quick Look at a Promising Phase III Breast Cancer Therapy @GreenwichLS is making major strides in the fight against breast cancer. Its lead immunotherapy candidate GLSI-100 is now in a global Phase III trial (FLAMINGO-01) spanning [---] sites across the U.S. and Europe targeting up to [---] HER2+ breast cancer patients. Why This Matters to Investors: - Breakthrough Potential: Aims to reduce recurrence rates by over 80% outperforming current HER2 therapies. - Robust Safety Profile: Supported by ongoing Data Safety Monitoring Board reviews with no changes required."
X Link 2025-07-22T13:40Z [----] followers, [---] engagements

"🎥 FatPipe $FATN CEO Interview: Inside a Profitable High-Margin Software Business Dont miss this exclusive conversation with Ragula Bhaskar PhD President & CEO of @FatPipe_Inc $FATN a leader in secure software-defined networking. 💡 Why Investors Should Watch: Positioned at the intersection of SD-WAN SASE and NMS: a $49B+ TAM by [----] 90%+ gross margins and a recurring revenue model Global footprint with over [----] enterprise customers 🔒 Backed by patented tech and a pure-play focus on mission-critical infrastructure FatPipe is delivering results and scaling smart. 📺 Watch Now and hear how"
X Link 2025-07-23T13:25Z [----] followers, [---] engagements

"📢 Mark Your Calendars: FatPipe $FATN Investor Webinar on August [--] Join @FatPipe_Incs leadership team on Thursday August [--] at 4:15 PM EST for a live investor webinar. Why Investors Should Tune In: $5.2M net income on $18.7M revenue 90%+ gross margins 35% adj. EBITDA margin Positioned in $49B+ TAM across SD-WAN SASE NMS Discover how this small-cap software leader is scaling secure enterprise networking worldwide. $FATN $CSCO $ORCL $HPE $FTNT https://www.redchip.com/webinar/FATN/89527003978utm_source=X&utm_medium=post&utm_campaign=FATN_webinar"
X Link 2025-07-24T16:27Z [----] followers, [---] engagements

"⚛ Greenwich LifeSciences $GLSI: A Quick Look at a Promising Phase III Breast Cancer Therapy @GreenwichLS is making major strides in the fight against breast cancer. Its lead immunotherapy candidate GLSI-100 is now in a global Phase III trial (FLAMINGO-01) spanning [---] sites across the U.S. and Europe targeting up to [---] HER2+ breast cancer patients. Why This Matters to Investors: - Breakthrough Potential: Aims to reduce recurrence rates by over 80% outperforming current HER2 therapies. - Robust Safety Profile: Supported by ongoing Data Safety Monitoring Board reviews with no changes required."
X Link 2025-07-29T13:40Z [----] followers, [---] engagements

"🤖 FatPipe $FATN: Solid Q1 FY26 Performance Marks Strong Public Debut @FatPipe_Inc reported its first quarterly earnings since going public showcasing financial strength and operational momentum: Revenue Growth: Total product revenue up 16.2% YoY reaching $3.9M Improved Profitability: Net income rose 22% YoY; adjusted EBITDA increased 10% Gross Margin Expansion: Reached 94% up from 92% in Q1 FY25 Industry Recognition: Won [----] MSP Today Product of the Year for Total Security [---] Why It Matters for Investors: $FATN's inaugural public quarter highlights scalable revenue streams strong margins"
X Link 2025-07-30T13:39Z [----] followers, [---] engagements

"🗓 [--] Week to Go: FatPipe $FATN Investor Webinar on August [--] @FatPipe_Inc is delivering growth and profitability in enterprise networking: hear directly from the team behind the strategy. $FATN at a glance: Serving 2500+ customers globally 27.7% net margin 35% adj. EBITDA margin High-margin recurring software revenue Find out why $FATN could be one of the most capital-efficient SaaS providers in the industry $FATN $CSCO $ORCL $HPE $FTNT https://www.redchip.com/webinar/FATN/89527003978utm_source=X&utm_medium=post&utm_campaign=FATN_webinar"
X Link 2025-07-31T16:08Z [----] followers, [---] engagements

"🚌 GreenPower Motor Company $GP Lands $5M+ EV School Bus Deal with State of New Mexico @GreenPowerBus has secured a multi-year contract valued at over $5 million with New Mexico to launch a state-wide all-electric school bus pilot program. The initiative will deploy the companys purpose-built Nano BEAST BEAST and Mega BEAST buses across five rotating rounds per school year supported by full charging infrastructure and training. Why This Matters to Investors: Strategic State Partnership: Expands $GP's footprint with a government-backed pilot focused on zero-emission transport. High-Value"
X Link 2025-08-04T13:35Z [----] followers, [---] engagements

"RedChip Investor Webinar with GreenPower Motor Company (Nasdaq: GP) https://x.com/i/broadcasts/1PlKQMMVerqKE https://x.com/i/broadcasts/1PlKQMMVerqKE"
X Link 2025-08-04T20:05Z [----] followers, [---] engagements

"⚛ Greenwich LifeSciences $GLSI: A Quick Look at a Promising Phase III Breast Cancer Therapy @GreenwichLS is making major strides in the fight against breast cancer. Its lead immunotherapy candidate GLSI-100 is now in a global Phase III trial (FLAMINGO-01) spanning [---] sites across the U.S. and Europe targeting up to [---] HER2+ breast cancer patients. Why This Matters to Investors: - Breakthrough Potential: Aims to reduce recurrence rates by over 80% outperforming current HER2 therapies. - Robust Safety Profile: Supported by ongoing Data Safety Monitoring Board reviews with no changes required."
X Link 2025-08-05T13:40Z [----] followers, [---] engagements

"📢 Join @ASPIsotopes $ASPI CEO Paul Mann for a Live Investor Webinar on August [--] @ 4:15 PM ET Hear directly from leadership as $ASPI transitions from development to commercialization with strategic updates on: Multi-year isotope supply agreements Commercial production milestones HALEU strategy with @TerraPower @RenergenJHB $REN acquisition outlook 🎯 Dont miss this opportunity to engage with a key player in the global isotope market. 🔗 Register Now: $ASPI $SMR $NNE $OKLO $UUUU $CEG $VST $CCJ $UEC $LEU $GEV $BEP https://bit.ly/45x7Qco https://bit.ly/45x7Qco"
X Link 2025-08-05T14:26Z [----] followers, [----] engagements

"Tomorrow at 4:15 PM EST: Live Webinar with @FatPipe_Inc $FATN Dont miss your chance to hear from a profitable small-cap innovator in secure cloud-optimized networking. 📊 Key Highlights: Growing global presence in U.S. India & Southeast Asia Deep IP portfolio + patented SD-WAN tech Strong FCF lean operating model 🔗 $FATN $CSCO $ORCL $HPE $FTNT #TechStocks #Networking #SDWAN #SASE #CloudInfrastructure #FinancialNews https://www.redchip.com/webinar/FATN/89527003978utm_source=X&utm_medium=post&utm_campaign=FATN_webinar"
X Link 2025-08-06T16:04Z [----] followers, [---] engagements

"🔔 Starting Soon: @FatPipe_Inc $FATN Live Webinar Join now for insights on growth profitability and global network innovation. 🔗 $FATN $CSCO $ORCL $HPE $FTNT #NASDAQ #TechStocks #Networking #SDWAN #SASE #CloudInfrastructure #FinancialNews https://www.redchip.com/webinar/FATN/89527003978utm_source=X&utm_medium=post&utm_campaign=FATN_webinar https://www.redchip.com/webinar/FATN/89527003978utm_source=X&utm_medium=post&utm_campaign=FATN_webinar"
X Link 2025-08-07T19:45Z [----] followers, [---] engagements

"Join @FatPipe_Inc $FATN's Co-Founder on our investor webinar: live now $FATN $CSCO $ORCL $HPE $FTNT RedChip Investor Webinar with FatPipe Inc. (Nasdaq: FATN) https://t.co/64V8aLQRXZ RedChip Investor Webinar with FatPipe Inc. (Nasdaq: FATN) https://t.co/64V8aLQRXZ"
X Link 2025-08-07T20:38Z [----] followers, [---] engagements

"🏆 FatPipe Inc. $FATN: Ranked #1 for Product & Support in [----] SD-WAN Midmarket Report @FatPipe_Inc has secured the top spots for both Product and Support in Info-Tech Research Groups [----] SD-WAN Midmarket Report based on verified user reviews. Why This Matters to Investors: Exceptional User Satisfaction: Net Emotional Footprint of +96 93% satisfaction with product features and 97% likelihood to recommend. Market Leadership: Recognition underscores $FATN's position as a leading provider of enterprise-grade SD-WAN solutions with integrated cybersecurity and real-time monitoring. Growth"
X Link 2025-08-08T13:37Z [----] followers, [---] engagements

"⚛ Greenwich LifeSciences $GLSI: A Quick Look at a Promising Phase III Breast Cancer Therapy @GreenwichLS is making major strides in the fight against breast cancer. Its lead immunotherapy candidate GLSI-100 is now in a global Phase III trial (FLAMINGO-01) spanning [---] sites across the U.S. and Europe targeting up to [---] HER2+ breast cancer patients. Why This Matters to Investors: - Breakthrough Potential: Aims to reduce recurrence rates by over 80% outperforming current HER2 therapies. - Robust Safety Profile: Supported by ongoing Data Safety Monitoring Board reviews with no changes required."
X Link 2025-08-12T13:40Z [----] followers, [---] engagements

"⚛ Greenwich LifeSciences $GLSI: A Quick Look at a Promising Phase III Breast Cancer Therapy @GreenwichLS is making major strides in the fight against breast cancer. Its lead immunotherapy candidate GLSI-100 is now in a global Phase III trial (FLAMINGO-01) spanning [---] sites across the U.S. and Europe targeting up to [---] HER2+ breast cancer patients. Why This Matters to Investors: - Breakthrough Potential: Aims to reduce recurrence rates by over 80% outperforming current HER2 therapies. - Robust Safety Profile: Supported by ongoing Data Safety Monitoring Board reviews with no changes required."
X Link 2025-08-19T13:40Z [----] followers, [---] engagements

"📈 @FatPipe_Inc $FATN: [---] New Customers Propel Q1 FY26 Growth FatPipe added [---] new customers in Q1 FY26 driving 16.2% year-over-year product revenue growth. The companys unified SD-WAN SASE cybersecurity and NMS platform features patented multi-path routing and sub-second failover to simplify and secure distributed networks. Why this matters for investors: Expanding recurring revenue base supported by a subscription model Differentiated tech stack with [--] U.S. patents and deep observability Diversified footprint of 2700+ customers across government healthcare financial services education"
X Link 2025-08-21T13:47Z [----] followers, [---] engagements

Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing